date
date32 | stock
stringclasses 98
values | title
stringlengths 13
158
| content
stringlengths 2
15k
| trading_date
timestamp[ns] | exact_trading_date
timestamp[ns] | ts_-30
float64 0.23
2.5k
| ts_-29
float64 0.22
2.62k
| ts_-28
float64 0.22
2.64k
| ts_-27
float64 0.23
2.65k
| ts_-26
float64 0.23
2.65k
| ts_-25
float64 0.23
2.57k
| ts_-24
float64 0.23
2.48k
| ts_-23
float64 0.25
2.48k
| ts_-22
float64 0.25
2.51k
| ts_-21
float64 0.25
2.62k
| ts_-20
float64 0.24
2.64k
| ts_-19
float64 0.25
2.65k
| ts_-18
float64 0.25
2.62k
| ts_-17
float64 0.25
2.64k
| ts_-16
float64 0.24
2.65k
| ts_-15
float64 0.23
2.64k
| ts_-14
float64 0.24
2.65k
| ts_-13
float64 0.24
2.62k
| ts_-12
float64 0.23
2.64k
| ts_-11
float64 0.23
2.65k
| ts_-10
float64 0.23
2.57k
| ts_-9
float64 0.22
2.48k
| ts_-8
float64 0.22
2.49k
| ts_-7
float64 0.23
2.48k
| ts_-6
float64 0.24
2.51k
| ts_-5
float64 0.23
2.51k
| ts_-4
float64 0.23
2.62k
| ts_-3
float64 0.22
2.64k
| ts_-2
float64 0.22
2.65k
| ts_-1
float64 0.22
2.57k
| ts_0
float64 0.23
2.48k
| ts_1
float64 0.23
2.62k
| ts_2
float64 0.23
2.64k
| ts_3
float64 0.23
2.65k
| ts_4
float64 0.22
2.65k
| ts_5
float64 0.22
2.57k
| ts_6
float64 0.23
2.48k
| ts_7
float64 0.23
2.46k
| ts_8
float64 0.23
2.5k
| ts_9
float64 0.23
2.54k
| ts_10
float64 0.23
2.51k
| ts_11
float64 0.22
2.5k
| ts_12
float64 0.22
2.48k
| ts_13
float64 0.23
2.44k
| ts_14
float64 0.23
2.48k
| ts_15
float64 0.23
2.46k
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-03-11 | VRSK | Verisk Analytics goes ex-dividend tomorrow | Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, 8% increase from prior dividend of $0.25.
Payable March 31; for shareholders of record March 13; ex-div March 12.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2020-03-12T00:00:00 | 2020-03-12T00:00:00 | 164.179993 | 164.710007 | 162.470001 | 165.220001 | 168.130005 | 168.559998 | 168.949997 | 169.119995 | 169.940002 | 167.889999 | 169.279999 | 170.669998 | 171.380005 | 171.559998 | 169.740005 | 169.389999 | 168.690002 | 167.580002 | 162.820007 | 163.529999 | 155.789993 | 155.110001 | 163.130005 | 160.399994 | 169.179993 | 164.970001 | 163.369995 | 147.919998 | 156.740005 | 151.679993 | 139.490005 | 145.610001 | 130.059998 | 144.710007 | 135.110001 | 136.479996 | 124.25 | 121.18 | 137.279999 | 134.300003 | 142.100006 | 137.770004 | 146.869995 | 139.380005 | 140.779999 | 142.990005 |
2020-05-04 | VRSK | Verisk Analytics Q1 2020 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q1 earnings results on Tuesday, May 5th, after market close.
The consensus EPS Estimate is $1.13 (+9.7% Y/Y) and the consensus Revenue Estimate is $677.79M (+8.4% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 38% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 0 upward revisions and 4 downward. | 2020-05-05T00:00:00 | 2020-05-05T00:00:00 | 121.18 | 137.279999 | 134.300003 | 142.100006 | 137.770004 | 146.869995 | 139.380005 | 140.779999 | 142.990005 | 141.649994 | 147.740005 | 147.169998 | 148.699997 | 148.259995 | 144.160004 | 150.300003 | 147.130005 | 149.110001 | 153.789993 | 149.320007 | 145.210007 | 151.199997 | 147.699997 | 148.539993 | 151.800003 | 151.789993 | 153.070007 | 152.830002 | 153.449997 | 154.460007 | 157.490005 | 155.179993 | 158.270004 | 159.570007 | 160.710007 | 156.600006 | 154.429993 | 153.899994 | 154.559998 | 158.320007 | 158.059998 | 159.539993 | 156.839996 | 157.279999 | 160.460007 | 163.460007 |
2020-05-05 | VRSK | Verisk Analytics declares $0.27 dividend | Verisk Analytics (NASDAQ:VRSK) declares $0.27/share quarterly dividend, in line with previous.
Forward yield 0.69%
Payable June 30; for shareholders of record June 15; ex-div June 12.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2020-05-06T00:00:00 | 2020-05-06T00:00:00 | 137.279999 | 134.300003 | 142.100006 | 137.770004 | 146.869995 | 139.380005 | 140.779999 | 142.990005 | 141.649994 | 147.740005 | 147.169998 | 148.699997 | 148.259995 | 144.160004 | 150.300003 | 147.130005 | 149.110001 | 153.789993 | 149.320007 | 145.210007 | 151.199997 | 147.699997 | 148.539993 | 151.800003 | 151.789993 | 153.070007 | 152.830002 | 153.449997 | 154.460007 | 157.490005 | 155.179993 | 158.270004 | 159.570007 | 160.710007 | 156.600006 | 154.429993 | 153.899994 | 154.559998 | 158.320007 | 158.059998 | 159.539993 | 156.839996 | 157.279999 | 160.460007 | 163.460007 | 168.339996 |
2020-05-05 | VRSK | Verisk Analytics EPS beats by $0.04, beats on revenue | Verisk Analytics (NASDAQ:VRSK): Q1 Non-GAAP EPS of $1.17 beats by $0.04; GAAP EPS of $1.04 beats by $0.12.
Revenue of $689.8M (+10.4% Y/Y) beats by $12.01M.
Press Release | 2020-05-06T00:00:00 | 2020-05-06T00:00:00 | 137.279999 | 134.300003 | 142.100006 | 137.770004 | 146.869995 | 139.380005 | 140.779999 | 142.990005 | 141.649994 | 147.740005 | 147.169998 | 148.699997 | 148.259995 | 144.160004 | 150.300003 | 147.130005 | 149.110001 | 153.789993 | 149.320007 | 145.210007 | 151.199997 | 147.699997 | 148.539993 | 151.800003 | 151.789993 | 153.070007 | 152.830002 | 153.449997 | 154.460007 | 157.490005 | 155.179993 | 158.270004 | 159.570007 | 160.710007 | 156.600006 | 154.429993 | 153.899994 | 154.559998 | 158.320007 | 158.059998 | 159.539993 | 156.839996 | 157.279999 | 160.460007 | 163.460007 | 168.339996 |
2020-08-03 | VRSK | Verisk Analytics Q2 2020 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q2 earnings results on Tuesday, August 4th, after market close.
The consensus EPS Estimate is $1.19 (+8.2% Y/Y) and the consensus Revenue Estimate is $685.84M (+5.1% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 4 upward revisions and 11 downward. Revenue estimates have seen 1 upward revision and 11 downward. | 2020-08-04T00:00:00 | 2020-08-04T00:00:00 | 167.270004 | 166.809998 | 163.690002 | 166.210007 | 162.889999 | 164.339996 | 170.199997 | 172.419998 | 173.110001 | 173.559998 | 172.929993 | 172.830002 | 173.199997 | 174.169998 | 172.850006 | 174.589996 | 175.399994 | 175.419998 | 178.399994 | 181.600006 | 180.679993 | 181.350006 | 180.630005 | 179.779999 | 183.210007 | 182.429993 | 187.649994 | 187.169998 | 188.710007 | 186.960007 | 187.720001 | 186.660004 | 189.559998 | 191.160004 | 189.649994 | 187.889999 | 190.429993 | 190.710007 | 189.149994 | 189.070007 | 189.130005 | 187.240005 | 185.860001 | 185.649994 | 185.110001 | 185.970001 |
2020-08-04 | VRSK | Verisk Analytics EPS beats by $0.10, misses on revenue | Verisk Analytics (NASDAQ:VRSK): Q2 Non-GAAP EPS of $1.29 beats by $0.10; GAAP EPS of $1.08 beats by $0.10.
Revenue of $678.8M (+4.0% Y/Y) misses by $7.04M.
Shares -0.31%.
Press Release | 2020-08-05T00:00:00 | 2020-08-05T00:00:00 | 166.809998 | 163.690002 | 166.210007 | 162.889999 | 164.339996 | 170.199997 | 172.419998 | 173.110001 | 173.559998 | 172.929993 | 172.830002 | 173.199997 | 174.169998 | 172.850006 | 174.589996 | 175.399994 | 175.419998 | 178.399994 | 181.600006 | 180.679993 | 181.350006 | 180.630005 | 179.779999 | 183.210007 | 182.429993 | 187.649994 | 187.169998 | 188.710007 | 186.960007 | 187.720001 | 186.660004 | 189.559998 | 191.160004 | 189.649994 | 187.889999 | 190.429993 | 190.710007 | 189.149994 | 189.070007 | 189.130005 | 187.240005 | 185.860001 | 185.649994 | 185.110001 | 185.970001 | 186.410004 |
2020-09-11 | VRSK | Verisk acquires Franco Signor for $160M | Verisk (NASDAQ:VRSK)
acquires Franco Signor, a highly-regarded medicare secondary payer service provider.
Franco Signor will become part of the Verisk's Claims Partner business, a leading provider of MSP compliance and other analytic claim services.
Purchase price was $160M
Claims Partners and Franco Signor will be combining forces to provide the single best resource for Medicare compliance.
âWe anticipate that this acquisition will have substantive long-term advantages for the industry, as Verisk will now be able to offer unparalleled guidance and an all-inclusive solution suite for all aspects of an insurerâs Medicare compliance needs.â said Mark Anquillare, COO.
Take a brief look at the company's growing figures here. | 2020-09-12T00:00:00 | 2020-09-14T00:00:00 | 188.710007 | 186.960007 | 187.720001 | 186.660004 | 189.559998 | 191.160004 | 189.649994 | 187.889999 | 190.429993 | 190.710007 | 189.149994 | 189.070007 | 189.130005 | 187.240005 | 185.860001 | 185.649994 | 185.110001 | 185.970001 | 186.410004 | 186.610001 | 187.350006 | 186.669998 | 187.690002 | 192.789993 | 187.279999 | 182.770004 | 178.089996 | 182.960007 | 181.5 | 181.639999 | 185.080002 | 187.839996 | 186.789993 | 184.789993 | 181.580002 | 178.679993 | 180.389999 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 |
2020-09-11 | VRSK | Verisk Analytics goes ex-dividend on Monday | Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, in line with previous.
Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2020-09-12T00:00:00 | 2020-09-14T00:00:00 | 188.710007 | 186.960007 | 187.720001 | 186.660004 | 189.559998 | 191.160004 | 189.649994 | 187.889999 | 190.429993 | 190.710007 | 189.149994 | 189.070007 | 189.130005 | 187.240005 | 185.860001 | 185.649994 | 185.110001 | 185.970001 | 186.410004 | 186.610001 | 187.350006 | 186.669998 | 187.690002 | 192.789993 | 187.279999 | 182.770004 | 178.089996 | 182.960007 | 181.5 | 181.639999 | 185.080002 | 187.839996 | 186.789993 | 184.789993 | 181.580002 | 178.679993 | 180.389999 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 |
2020-09-22 | VRSK | AIR Worldwide launched updated Multiple Peril Crop Insurance for China | Catastrophe risk modeling firm AIR Worldwide (AIR), a Verisk (NASDAQ:VRSK) business, released an updated Multiple Peril Crop Insurance (MPCI) Model for China to support probabilistic assessments for five newly modeled crop lines of business and a newly modeled sub-peril.
This update also includes a new livestock module that adds six additional lines of business and two new sub-perils. Dr. Jeff Amthor, assistant vice president, AIR Worldwide, said, âThe MPCI Model for China captures the severity, frequency, and location of drought, flood, wind, frost, and heat events nationwide, covering over 90% of the weather-related crop losses.â | 2020-09-23T00:00:00 | 2020-09-23T00:00:00 | 187.889999 | 190.429993 | 190.710007 | 189.149994 | 189.070007 | 189.130005 | 187.240005 | 185.860001 | 185.649994 | 185.110001 | 185.970001 | 186.410004 | 186.610001 | 187.350006 | 186.669998 | 187.690002 | 192.789993 | 187.279999 | 182.770004 | 178.089996 | 182.960007 | 181.5 | 181.639999 | 185.080002 | 187.839996 | 186.789993 | 184.789993 | 181.580002 | 178.679993 | 180.389999 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 | 179.789993 | 183.029999 | 184.899994 | 187.179993 | 192.75 | 193.649994 | 191.759995 |
2020-10-13 | VRSK | Ford and Verisk Analytics join hands to offer telematics data to insurers | Verisk (VRSK
+0.5%)Â announces that Ford Motor Company (F
-0.1%) has joined the Verisk Data Exchange.
Owners of eligible Ford and Lincoln vehicles will soon have easy access to usage-based insurance programs from the many U.S. auto insurers that connect to the Exchangeâincluding three of the ten largest U.S. carriers.
Usage-based insurance can give drivers greater transparency and control over their insurance costs.
âFord is committed to connecting our customers to valuable services that can help them reduce their total cost of ownership and get more out of their Ford vehicle â usage-based insurance is a great opportunity to do that,â said Alex Purdy, director of business operations, enterprise connectivity, Ford Motor Company. | 2020-10-14T00:00:00 | 2020-10-14T00:00:00 | 187.690002 | 192.789993 | 187.279999 | 182.770004 | 178.089996 | 182.960007 | 181.5 | 181.639999 | 185.080002 | 187.839996 | 186.789993 | 184.789993 | 181.580002 | 178.679993 | 180.389999 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 | 179.789993 | 183.029999 | 184.899994 | 187.179993 | 192.75 | 193.649994 | 191.759995 | 192.020004 | 192.470001 | 188.5 | 190.360001 | 189.179993 | 188.880005 | 189.25 | 185.490005 | 185.149994 | 179.490005 | 179.220001 | 177.970001 | 182.149994 | 187.949997 | 196.389999 |
2020-10-14 | VRSK | AIR Worldwide estimates $1-$3B insured losses for Hurricane Delta | Catastrophe risk modeling firm AIR Worldwide, a Verisk (NASDAQ:VRSK) business, estimates industry insured losses to onshore property resulting from Hurricane Delta's winds and storm surge will range from $1 to $3B.
Included in AIR's estimates are losses to onshore residential, commercial, and industrial properties and automobiles for their building, contents, and time element coverage. | 2020-10-15T00:00:00 | 2020-10-15T00:00:00 | 192.789993 | 187.279999 | 182.770004 | 178.089996 | 182.960007 | 181.5 | 181.639999 | 185.080002 | 187.839996 | 186.789993 | 184.789993 | 181.580002 | 178.679993 | 180.389999 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 | 179.789993 | 183.029999 | 184.899994 | 187.179993 | 192.75 | 193.649994 | 191.759995 | 192.020004 | 192.470001 | 188.5 | 190.360001 | 189.179993 | 188.880005 | 189.25 | 185.490005 | 185.149994 | 179.490005 | 179.220001 | 177.970001 | 182.149994 | 187.949997 | 196.389999 | 194.410004 |
2020-11-03 | VRSK | Verisk Analytics Q3 2020 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q3 earnings results on Wednesday, November 4th, after market close.
The consensus EPS Estimate is $1.20 (+7.1% Y/Y) and the consensus Revenue Estimate is $692.14M (+6.0% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 7 upward revisions and 8 downward. Revenue estimates have seen 5 upward revisions and 9 downward. | 2020-11-04T00:00:00 | 2020-11-04T00:00:00 | 177.080002 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 | 179.789993 | 183.029999 | 184.899994 | 187.179993 | 192.75 | 193.649994 | 191.759995 | 192.020004 | 192.470001 | 188.5 | 190.360001 | 189.179993 | 188.880005 | 189.25 | 185.490005 | 185.149994 | 179.490005 | 179.220001 | 177.970001 | 182.149994 | 187.949997 | 196.389999 | 194.410004 | 197.350006 | 196.309998 | 195.100006 | 199.830002 | 199.179993 | 203.699997 | 205.25 | 205.279999 | 203.899994 | 205.720001 | 204.369995 | 198.119995 | 194.479996 | 195.619995 |
2020-11-04 | VRSK | Verisk Analytics EPS beats by $0.12, beats on revenue | Verisk Analytics (NASDAQ:VRSK): Q3 Non-GAAP EPS of $1.32 beats by $0.12; GAAP EPS of $1.12 beats by $0.17.
Revenue of $702.7M (+7.7% Y/Y) beats by $10.56M.
Press Release | 2020-11-05T00:00:00 | 2020-11-05T00:00:00 | 177.229996 | 181.339996 | 184.520004 | 184.380005 | 185.309998 | 185.639999 | 182.100006 | 181.789993 | 179.789993 | 183.029999 | 184.899994 | 187.179993 | 192.75 | 193.649994 | 191.759995 | 192.020004 | 192.470001 | 188.5 | 190.360001 | 189.179993 | 188.880005 | 189.25 | 185.490005 | 185.149994 | 179.490005 | 179.220001 | 177.970001 | 182.149994 | 187.949997 | 196.389999 | 194.410004 | 197.350006 | 196.309998 | 195.100006 | 199.830002 | 199.179993 | 203.699997 | 205.25 | 205.279999 | 203.899994 | 205.720001 | 204.369995 | 198.119995 | 194.479996 | 195.619995 | 198.229996 |
2020-11-30 | VRSK | S&P Global all-stock $44B deal undervalues IHS Markit, Truist analyst says | S&P Global's (NYSE:SPGI) agreement to buy IHS Markit (NYSE:INFO) at ~$44B enterprise value, or $98 per share in stock, materially undervalues INFO, according to Truist analyst Andrew Jeffrey.
The ~6% premium to INFO's recent close is disappointing when considering IHS's multi-year organic revenue, EBITDA, and free cash flow compounding outlook, the analyst wrote in a note to clients
The combined entity's expected 6.5%-8% CY22-23 organic revenue growth outlook is "materially comparable to IHS's stand-alone outlook" and "highlights what we view as the dubious merits of the combination," Jeffrey said.
Points out that the proposed merger would value INFO at ~21.7x CY21E EBITDA, which is an about 11% discount to info services rival Verisk (NASDAQ:VRSK), he adds.
Jeffrey also finds it surprising that Markit's founder and current IHS Markit CEO Lance Uggla won't hold a leadership role in the combined SPGI/INFO.
"We are startled by this outcome given his entrepreneurial roots and the success he has achieved as IHS' CEO," Jeffrey said. "Little about this transaction makes sense to us."
He also doesn't see an rival suitors stepping up as the size of the transaction makes it prohibitive for private equity.
IHS Markit is up 6.9% in premarket trading, bringing the stock's price to $98.95.
See IHS Markit's enterprise value/EBITDA vs. S&P Global and Verisk over the past five years:
See how INFO's Quant factor grades stack up against SPGI, Verisk, and FactSet: | 2020-12-01T00:00:00 | 2020-12-01T00:00:00 | 188.5 | 190.360001 | 189.179993 | 188.880005 | 189.25 | 185.490005 | 185.149994 | 179.490005 | 179.220001 | 177.970001 | 182.149994 | 187.949997 | 196.389999 | 194.410004 | 197.350006 | 196.309998 | 195.100006 | 199.830002 | 199.179993 | 203.699997 | 205.25 | 205.279999 | 203.899994 | 205.720001 | 204.369995 | 198.119995 | 194.479996 | 195.619995 | 198.229996 | 198.309998 | 200.139999 | 195.990005 | 193.850006 | 195.679993 | 194.449997 | 194.929993 | 193.449997 | 192.199997 | 193.990005 | 194.770004 | 196.139999 | 195.880005 | 201.240005 | 204.470001 | 202.770004 | 201.929993 |
2020-12-11 | VRSK | Verisk Analytics goes ex-dividend on Monday | Verisk Analytics (NASDAQ:VRSK) had declared $0.27/share quarterly dividend, in line with previous.
Payable Dec. 31; for shareholders of record Dec. 15; ex-div Dec. 14.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2020-12-12T00:00:00 | 2020-12-14T00:00:00 | 177.970001 | 182.149994 | 187.949997 | 196.389999 | 194.410004 | 197.350006 | 196.309998 | 195.100006 | 199.830002 | 199.179993 | 203.699997 | 205.25 | 205.279999 | 203.899994 | 205.720001 | 204.369995 | 198.119995 | 194.479996 | 195.619995 | 198.229996 | 198.309998 | 200.139999 | 195.990005 | 193.850006 | 195.679993 | 194.449997 | 194.929993 | 193.449997 | 192.199997 | 193.990005 | 194.770004 | 196.139999 | 195.880005 | 201.240005 | 204.470001 | 202.770004 | 201.929993 | 199.970001 | 201.229996 | 207.979996 | 205.669998 | 205.779999 | 207.589996 | 202.880005 | 201.970001 | 200.059998 |
2020-12-15 | VRSK | Verisk to acquire consumer behavioral data and intelligence firm, Jornaya | Verisk (NASDAQ:VRSK) inks agreement to acquire Jornaya, a leading provider of consumer behavioral data and intelligence.
The acquisition will add Jornaya's proprietary view of consumer buying journeys to Verisk's marketing solutions for the insurance and financial services markets.
With this acquisition, VRSK clients will have the intelligence and agility to time and tailor interactions based on actual in-market behaviors.
Financial terms weren't disclosed | 2020-12-16T00:00:00 | 2020-12-16T00:00:00 | 187.949997 | 196.389999 | 194.410004 | 197.350006 | 196.309998 | 195.100006 | 199.830002 | 199.179993 | 203.699997 | 205.25 | 205.279999 | 203.899994 | 205.720001 | 204.369995 | 198.119995 | 194.479996 | 195.619995 | 198.229996 | 198.309998 | 200.139999 | 195.990005 | 193.850006 | 195.679993 | 194.449997 | 194.929993 | 193.449997 | 192.199997 | 193.990005 | 194.770004 | 196.139999 | 195.880005 | 201.240005 | 204.470001 | 202.770004 | 201.929993 | 199.970001 | 201.229996 | 207.979996 | 205.669998 | 205.779999 | 207.589996 | 202.880005 | 201.970001 | 200.059998 | 200.970001 | 200.899994 |
2021-02-01 | VRSK | Enigma Technologies collaborates with Verisk Financial | Verisk Financial (VRSK
+1.7%) and Enigma Technologies announce a strategic collaboration.
Enigma Technologies, a data science company that collects and analyzes information on the health and identity of every U.S. business. Through the Verisk collaboration, Enigma is launching a new solution that allows clients to see and understand how small business revenues are trending in near real-time.
Combining these revenue trends with Enigma's proprietary entity resolution and machine learning techniques provides actionable estimates about the financial health of more than 20M small businesses. These insights enable risk, underwriting, and marketing teams at financial institutions to better segment and serve small businesses.
Enigma to joins a consortium of banks, payments processors, and financial institutions to provide trustworthy intelligence about a small business's financial health. | 2021-02-02T00:00:00 | 2021-02-02T00:00:00 | 201.240005 | 204.470001 | 202.770004 | 201.929993 | 199.970001 | 201.229996 | 207.979996 | 205.669998 | 205.779999 | 207.589996 | 202.880005 | 201.970001 | 200.059998 | 200.970001 | 200.899994 | 197.869995 | 196.639999 | 196.880005 | 193.880005 | 190.020004 | 191.369995 | 194.710007 | 194.869995 | 192.759995 | 188.679993 | 188.5 | 184.270004 | 186.429993 | 183.5 | 185.940002 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 |
2021-02-22 | VRSK | Verisk Analytics Q4 2020 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q4 earnings results on Tuesday, February 23rd, after market close.
The consensus EPS Estimate is $1.30 (+15.0% Y/Y) and the consensus Revenue Estimate is $717.04M (+5.9% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 2 upward revisions and 0 downward. | 2021-02-23T00:00:00 | 2021-02-23T00:00:00 | 200.899994 | 197.869995 | 196.639999 | 196.880005 | 193.880005 | 190.020004 | 191.369995 | 194.710007 | 194.869995 | 192.759995 | 188.679993 | 188.5 | 184.270004 | 186.429993 | 183.5 | 185.940002 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 | 164.289993 | 163.850006 | 167.039993 | 166.380005 | 164.809998 | 161.649994 | 168.119995 | 171.649994 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 |
2021-02-23 | VRSK | Verisk Analytics raises dividend by 7% to $0.29 | Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, 7.4% increase from prior dividend of $0.27.
Forward yield 0.63%
Payable March 31; for shareholders of record March 15; ex-div March 12.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2021-02-24T00:00:00 | 2021-02-24T00:00:00 | 197.869995 | 196.639999 | 196.880005 | 193.880005 | 190.020004 | 191.369995 | 194.710007 | 194.869995 | 192.759995 | 188.679993 | 188.5 | 184.270004 | 186.429993 | 183.5 | 185.940002 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 | 164.289993 | 163.850006 | 167.039993 | 166.380005 | 164.809998 | 161.649994 | 168.119995 | 171.649994 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 | 171.940002 |
2021-02-23 | VRSK | Verisk Analytics EPS misses by $0.03, misses on revenue | Verisk Analytics (NASDAQ:VRSK): Q4 Non-GAAP EPS of $1.27 misses by $0.03; GAAP EPS of $1.07 misses by $0.01.
Revenue of $713.3M (+5.4% Y/Y) misses by $3.74M.
Press Release | 2021-02-24T00:00:00 | 2021-02-24T00:00:00 | 197.869995 | 196.639999 | 196.880005 | 193.880005 | 190.020004 | 191.369995 | 194.710007 | 194.869995 | 192.759995 | 188.679993 | 188.5 | 184.270004 | 186.429993 | 183.5 | 185.940002 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 | 164.289993 | 163.850006 | 167.039993 | 166.380005 | 164.809998 | 161.649994 | 168.119995 | 171.649994 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 | 171.940002 |
2021-03-08 | VRSK | Verisk upgraded at Deutsche Bank on 'attractive buying opportunity' | Citing the recent pullback, Deutsche Bank upgrades Verisk Analytics (NASDAQ:VRSK) from Hold to Buy with a $196 price target, implying a 17% upside.
Analyst Ashish Sabadra sees an "attractive buying opportunity" ahead of revenue growth improvement, driven by sustained subscription revenue and transaction revenue recovering from its pandemic hit.
The analyst also praises Verisk's "commanding market position in defensive end markets" and tailwinds from the secular digitization trends.
Verisk shares are up 1% pre-market to $169.76.
VRSK is down over 10% in the past month since the company reported Q4 revenue and EPS misses. | 2021-03-09T00:00:00 | 2021-03-09T00:00:00 | 188.679993 | 188.5 | 184.270004 | 186.429993 | 183.5 | 185.940002 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 | 164.289993 | 163.850006 | 167.039993 | 166.380005 | 164.809998 | 161.649994 | 168.119995 | 171.649994 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 | 171.940002 | 170.550003 | 171.869995 | 174.820007 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 |
2021-03-16 | VRSK | Verisk expands into group life insurance market by acquiring assets and capabilities of 4C Solutions | FAST, a Verisk (VRSK
-0.1%) business is acquiring assets and capabilities of 4C Solutions, a software advisory firm in group life insurance.
Transaction terms not dislcosed.
The acquisition will help insurers meet the rapidly changing coverage needs of companies and their employees.
"Managing group life insurance can be a major challenge for insurers, many of whom rely on decades-old technology to help employees obtain the coverage they need," said Tom Famularo, managing director and co-founder of FAST. "The addition of 4Câs capabilities will help us serve the group life market. Our scalable, no-code solutions can be implemented in months and will provide group insurers with tools to improve operational efficiency and transform the customer experience." | 2021-03-17T00:00:00 | 2021-03-17T00:00:00 | 188.699997 | 186.869995 | 188.389999 | 187.429993 | 188.860001 | 190.509995 | 190.820007 | 189.300003 | 189.5 | 188.360001 | 188.559998 | 192.020004 | 190.490005 | 186.240005 | 185.360001 | 167.529999 | 164.289993 | 163.850006 | 167.039993 | 166.380005 | 164.809998 | 161.649994 | 168.119995 | 171.649994 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 | 171.940002 | 170.550003 | 171.869995 | 174.820007 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 | 176.690002 | 179.809998 | 181.550003 | 180.889999 | 179.990005 | 181.210007 |
2021-04-20 | VRSK | Archegos co-founder Mills resigns from Verisk Analytics board | Verisk Analytics (NASDAQ:VRSK)Â announces the resignation of board director Andrew G. Mills, effective April 18. Mills joined the board in 2002.
Mills was the executive chairman and co-CEO of Archegos Capital Management, the family office of Bill Hwang that imploded, causing damage to lenders like Credit Suisse. | 2021-04-21T00:00:00 | 2021-04-21T00:00:00 | 174.419998 | 174.860001 | 173.210007 | 171.759995 | 174.589996 | 172.970001 | 171.940002 | 170.550003 | 171.869995 | 174.820007 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 | 176.690002 | 179.809998 | 181.550003 | 180.889999 | 179.990005 | 181.210007 | 182.699997 | 182.5 | 183.570007 | 181.949997 | 184.5 | 185.460007 | 184.529999 | 184.440002 | 185.380005 | 187.259995 | 188.880005 | 186.470001 | 187.199997 | 187.259995 | 188.600006 | 188.199997 | 188.550003 | 188.520004 | 172.630005 | 175.020004 | 178.770004 | 179.559998 | 175.080002 | 172 |
2021-05-03 | VRSK | Verisk Analytics Q1 2021 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q1 earnings results on Tuesday, May 4th, after market close.
The consensus EPS Estimate is $1.25 (+6.8% Y/Y) and the consensus Revenue Estimate is $726.5M (+5.3% Y/Y).
Analysts expect adjusted EBITDA of $347.5M with adjusted EBITDA margin of 47.9%.
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 75% of the time.
Over the last 3 months, EPS estimates have seen 4 upward revisions and 7 downward. Revenue estimates have seen 3 upward revisions and 5 downward. | 2021-05-04T00:00:00 | 2021-05-04T00:00:00 | 174.820007 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 | 176.690002 | 179.809998 | 181.550003 | 180.889999 | 179.990005 | 181.210007 | 182.699997 | 182.5 | 183.570007 | 181.949997 | 184.5 | 185.460007 | 184.529999 | 184.440002 | 185.380005 | 187.259995 | 188.880005 | 186.470001 | 187.199997 | 187.259995 | 188.600006 | 188.199997 | 188.550003 | 188.520004 | 172.630005 | 175.020004 | 178.770004 | 179.559998 | 175.080002 | 172 | 173.580002 | 175 | 172.940002 | 172.059998 | 173.070007 | 173.350006 | 173.509995 | 174.169998 | 173.699997 |
2021-05-04 | VRSK | Verisk Analytics declares $0.29 dividend | Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, in line with previous.
Forward yield 0.62%
Payable June 30; for shareholders of record June 15; ex-div June 14.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2021-05-05T00:00:00 | 2021-05-05T00:00:00 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 | 176.690002 | 179.809998 | 181.550003 | 180.889999 | 179.990005 | 181.210007 | 182.699997 | 182.5 | 183.570007 | 181.949997 | 184.5 | 185.460007 | 184.529999 | 184.440002 | 185.380005 | 187.259995 | 188.880005 | 186.470001 | 187.199997 | 187.259995 | 188.600006 | 188.199997 | 188.550003 | 188.520004 | 172.630005 | 175.020004 | 178.770004 | 179.559998 | 175.080002 | 172 | 173.580002 | 175 | 172.940002 | 172.059998 | 173.070007 | 173.350006 | 173.509995 | 174.169998 | 173.699997 | 172.979996 |
2021-05-04 | VRSK | Verisk Analytics EPS misses by $0.02, revenue in-line | Verisk Analytics (NASDAQ:VRSK): Q1 Non-GAAP EPS of $1.23 misses by $0.02; GAAP EPS of $1.03 misses by $0.02.
Revenue of $726.1M (+5.3% Y/Y) in-line.
Press Release | 2021-05-05T00:00:00 | 2021-05-05T00:00:00 | 177.589996 | 176.929993 | 174.779999 | 178.630005 | 180.320007 | 175.949997 | 176.690002 | 179.809998 | 181.550003 | 180.889999 | 179.990005 | 181.210007 | 182.699997 | 182.5 | 183.570007 | 181.949997 | 184.5 | 185.460007 | 184.529999 | 184.440002 | 185.380005 | 187.259995 | 188.880005 | 186.470001 | 187.199997 | 187.259995 | 188.600006 | 188.199997 | 188.550003 | 188.520004 | 172.630005 | 175.020004 | 178.770004 | 179.559998 | 175.080002 | 172 | 173.580002 | 175 | 172.940002 | 172.059998 | 173.070007 | 173.350006 | 173.509995 | 174.169998 | 173.699997 | 172.979996 |
2021-06-18 | VRSK | Wood Mackenzie expands energy transition expertise with the acquisition of Roskill | Wood Mackenzie, a Verisk (NASDAQ:VRSK) business, acquires Roskill, a privately-owned company and leader in metals and materials supply chain intelligence.
The commercial terms were not disclosed.
Neal Anderson, President of Wood Mackenzie: â..In particular, Roskill adds market-leading analysis, data, and insight on battery raw materials metals, which are an integral component of the energy transition.â
In addition, the Company also announces that Valerie Purvis will be assuming the role of Global Head of Metals & Mining, including Roskill. This appointment is in addition to Valerie's current responsibility as Global Head of the Chemicals business.
Press Release | 2021-06-19T00:00:00 | 2021-06-21T00:00:00 | 178.770004 | 179.559998 | 175.080002 | 172 | 173.580002 | 175 | 172.940002 | 172.059998 | 173.070007 | 173.350006 | 173.509995 | 174.169998 | 173.699997 | 172.979996 | 172.130005 | 172.830002 | 171.179993 | 172.679993 | 171.830002 | 172.649994 | 167.800003 | 169.5 | 169.919998 | 170.820007 | 172.199997 | 173.270004 | 172.570007 | 170.899994 | 172.990005 | 171.089996 | 174.910004 | 175.259995 | 171.699997 | 173.309998 | 174.699997 | 173.979996 | 174.330002 | 174.720001 | 176.800003 | 177.5 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 |
2021-06-22 | VRSK | Verisk business launches first-of-its-kind refinery intelligence tool | Wood Mackenzie, a Verisk business (NASDAQ:VRSK), is now offering Refinery I/O, a new tool providing daily refinery analytics from proprietary data sets.
The new tool will deliver more than 1,020 data points to users every day via API, along with weekly summary reports and supplemental analysis on significant events, such as weather incidents like hurricane season and Covid-19 developments, as they affect the U.S. and Canadian refineries.
âWith its operational efficiencies, not only does this product provide refinery-level granularity, which serves multiple client use cases, but it saves time analyzing internal processes.â
Press Release | 2021-06-23T00:00:00 | 2021-06-23T00:00:00 | 175.080002 | 172 | 173.580002 | 175 | 172.940002 | 172.059998 | 173.070007 | 173.350006 | 173.509995 | 174.169998 | 173.699997 | 172.979996 | 172.130005 | 172.830002 | 171.179993 | 172.679993 | 171.830002 | 172.649994 | 167.800003 | 169.5 | 169.919998 | 170.820007 | 172.199997 | 173.270004 | 172.570007 | 170.899994 | 172.990005 | 171.089996 | 174.910004 | 175.259995 | 171.699997 | 173.309998 | 174.699997 | 173.979996 | 174.330002 | 174.720001 | 176.800003 | 177.5 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 |
2021-08-02 | VRSK | Verisk Analytics Q2 2021 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q2 earnings results on Tuesday, August 3rd, after market close.
The consensus EPS Estimate is $1.33 (+3.1% Y/Y) and the consensus Revenue Estimate is $737.58M (+8.7% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 4 upward revisions and 7 downward. Revenue estimates have seen 6 upward revisions and 4 downward. | 2021-08-03T00:00:00 | 2021-08-03T00:00:00 | 174.910004 | 175.259995 | 171.699997 | 173.309998 | 174.699997 | 173.979996 | 174.330002 | 174.720001 | 176.800003 | 177.5 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 | 186.990005 | 184.309998 | 187.429993 | 187.089996 | 187.199997 | 188.389999 | 186.820007 | 186.699997 | 185.270004 | 187.809998 | 189.940002 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 |
2021-08-03 | VRSK | Verisk Analytics declares $0.29 dividend | Verisk Analytics (NASDAQ:VRSK) declares $0.29/share quarterly dividend, in line with previous.
Forward yield 0.62%
Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2021-08-04T00:00:00 | 2021-08-04T00:00:00 | 175.259995 | 171.699997 | 173.309998 | 174.699997 | 173.979996 | 174.330002 | 174.720001 | 176.800003 | 177.5 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 | 186.990005 | 184.309998 | 187.429993 | 187.089996 | 187.199997 | 188.389999 | 186.820007 | 186.699997 | 185.270004 | 187.809998 | 189.940002 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 |
2021-08-03 | VRSK | Verisk Analytics EPS misses by $0.16, beats on revenue | Verisk Analytics (NASDAQ:VRSK): Q2 Non-GAAP EPS of $1.17 misses by $0.16; GAAP EPS of $0.94 misses by $0.16.
Revenue of $747.5M (+10.1% Y/Y) beats by $9.92M.
Press Release | 2021-08-04T00:00:00 | 2021-08-04T00:00:00 | 175.259995 | 171.699997 | 173.309998 | 174.699997 | 173.979996 | 174.330002 | 174.720001 | 176.800003 | 177.5 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 | 186.990005 | 184.309998 | 187.429993 | 187.089996 | 187.199997 | 188.389999 | 186.820007 | 186.699997 | 185.270004 | 187.809998 | 189.940002 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 |
2021-08-16 | VRSK | Verisk picks industry veteran for human resources chief | Verisk (VRSK
+0.4%)
appointed 30-years industry veteran Sunita Holzer as EVP & chief human resources officer; she has HR leadership experience spans several industries, including those served by Verisk.
Recently, Holzer served as EVP & CHRO of Realogy; she also serves on South Jersey Industries board and is a Human Resources Management Department Advisory Board member at Rutgers School of Management and Labor Relations.
She succeeds Vince McCarthy, who stepped in a year and a half ago to lead the companyâs HR function. | 2021-08-17T00:00:00 | 2021-08-17T00:00:00 | 177.610001 | 182.089996 | 181.210007 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 | 186.990005 | 184.309998 | 187.429993 | 187.089996 | 187.199997 | 188.389999 | 186.820007 | 186.699997 | 185.270004 | 187.809998 | 189.940002 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 | 197.779999 | 199.520004 | 200.779999 | 201.759995 | 203.059998 | 204.600006 | 205.080002 | 203.110001 | 206.339996 |
2021-08-19 | VRSK | MRS taps Verisk’s voice analytics to screen for tobacco users | Management Research Services (MRS), a life insurance technology provider, is tapping Veriskâs (VRSK
+0.2%) proprietary voice analytics for integration into its telephonic medical interviews.
MRS will implement Veriskâs Tobacco Usage Propensity Model, which uses machine learning and AI, to analyze audio interviews and flag possible tobacco users. It will then determine if certain applicants need to submit to lab tests to verify their tobacco usage status.
Maroun Mourad, president of global underwriting at Verisk, commented on the integration, "Our model supports more straight-through processing, enabling the majority of applicants to avoid traditional testing and help obtain coverage more quickly. Itâs truly a win-win situation, since insurers can reduce premium leakage related to tobacco nondisclosure, which may cost the industry more than $10B in lost premiums over the next three years."
Veriskâs Tobacco Usage Propensity Model is part of a suite of advanced analytics, automation and machine learning solutions for life insurance underwriting, claim insights, life and pension analytics, actuarial and portfolio modeling and compliance and fraud detection. | 2021-08-20T00:00:00 | 2021-08-20T00:00:00 | 181.710007 | 180.020004 | 181.169998 | 182.330002 | 184.759995 | 186.990005 | 184.309998 | 187.429993 | 187.089996 | 187.199997 | 188.389999 | 186.820007 | 186.699997 | 185.270004 | 187.809998 | 189.940002 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 | 197.779999 | 199.520004 | 200.779999 | 201.759995 | 203.059998 | 204.600006 | 205.080002 | 203.110001 | 206.339996 | 204.860001 | 205.550003 | 205.020004 |
2021-09-13 | VRSK | Verisk's AIR estimates up to $30B insured losses from Hurricane Ida | Verisk Analytics' (NASDAQ:VRSK) AIR Worldwide provides insured loss estimates for Hurricane Ida to include impacts of inland flooding across the entirety of its track, including the Northeast.
AIR estimates that now its Idaâs insured industry losses will range from $20B to $30B. Wind and storm surge losses are estimated to range from $17B to $25B and private -market insured losses from inland flooding of $2.5B to $5B.
The model include insured physical damage to property, additional living expenses, and a 5% leakage, which is assumed to estimate the amount of damage/losses caused by storm surge attributed to wind for residential lines, among other factors.
According to AIR and Xactware analyses, "materials costs have gone up significantly in the past year from supply chain disruption in the construction market. Although these costs have moderated since their peak in July when they were 80% higher than September of last year, they remain about 30% higher."
Previously (Aug. 19): MRS taps Veriskâs voice analytics to screen for tobacco users | 2021-09-14T00:00:00 | 2021-09-14T00:00:00 | 190 | 188.490005 | 187.479996 | 189.910004 | 188.130005 | 187.460007 | 187.5 | 190.369995 | 190.130005 | 191.240005 | 191.399994 | 193 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 | 197.779999 | 199.520004 | 200.779999 | 201.759995 | 203.059998 | 204.600006 | 205.080002 | 203.110001 | 206.339996 | 204.860001 | 205.550003 | 205.020004 | 205.559998 | 204.559998 | 202.449997 | 201.100006 | 201.699997 | 202.949997 | 205.559998 | 208.970001 | 207.970001 | 203.729996 | 201.740005 | 202.369995 | 200.270004 | 199.990005 | 198.809998 | 201.630005 |
2021-09-29 | VRSK | Verisk Analytics enters collaboration with Insurance Regulatory Consultants | We Are/DigitalVision via Getty Images
Verisk (NASDAQ:VRSK) and Insurance Regulatory Consultants, a full-service state filing and regulatory compliance company enter into a new collaboration.
As part of the collaboration, Verisk to leverage the deep domain expertise and robust data of its ISO business to help new and existing insurers launch new products, improve their actuarial analysis and enhance their strategic decision making.
Further, IRC will assist the insurers in the development of these new products and guide them through the regulatory approval process. | 2021-09-30T00:00:00 | 2021-09-30T00:00:00 | 190.759995 | 194.679993 | 196.389999 | 197.509995 | 197.169998 | 197.820007 | 197.779999 | 199.520004 | 200.779999 | 201.759995 | 203.059998 | 204.600006 | 205.080002 | 203.110001 | 206.339996 | 204.860001 | 205.550003 | 205.020004 | 205.559998 | 204.559998 | 202.449997 | 201.100006 | 201.699997 | 202.949997 | 205.559998 | 208.970001 | 207.970001 | 203.729996 | 201.740005 | 202.369995 | 200.270004 | 199.990005 | 198.809998 | 201.630005 | 203.729996 | 206.740005 | 207.470001 | 206.529999 | 207.75 | 208.369995 | 211.550003 | 210.630005 | 211.039993 | 212.050003 | 211.929993 | 213.139999 |
2021-11-01 | VRSK | Verisk Analytics Q3 2021 Earnings Preview | Verisk Analytics (NASDAQ:VRSK) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close.
The consensus EPS Estimate is $1.36 (+3.0% Y/Y) and the consensus Revenue Estimate is $757.42M (+7.8% Y/Y).
Over the last 2 years, VRSK has beaten EPS estimates 50% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 14 upward revisions and 0 downward. Revenue estimates have seen 9 upward revisions and 2 downward. | 2021-11-02T00:00:00 | 2021-11-02T00:00:00 | 202.949997 | 205.559998 | 208.970001 | 207.970001 | 203.729996 | 201.740005 | 202.369995 | 200.270004 | 199.990005 | 198.809998 | 201.630005 | 203.729996 | 206.740005 | 207.470001 | 206.529999 | 207.75 | 208.369995 | 211.550003 | 210.630005 | 211.039993 | 212.050003 | 211.929993 | 213.139999 | 213.960007 | 212.020004 | 211.320007 | 207.880005 | 209.320007 | 210.270004 | 208.940002 | 209.309998 | 214.289993 | 216.600006 | 214.589996 | 214.910004 | 216.289993 | 213.820007 | 212.990005 | 216.270004 | 218.029999 | 222.600006 | 224.5 | 226.720001 | 230.029999 | 228.529999 | 229.320007 |
2021-11-02 | VRSK | Verisk acquires public record data aggregation firm Data Driven Safety | Verisk Analytics (NASDAQ:VRSK) has acquired public record data aggregation firm, Data Driven Safety (DDS).
DDS specializes in driver risk assessment. With its unique data collection and management platform, the firm collects information on traffic citations, vehicle accidents and driving records from public sources. It then synthesizes these data to provide insights to help insurers reduce costs, better manage risk and anticipate operational challenges.
The acquisition will expand Verisk's auto insurance analytics, providing insurers with information to further refine underwriting, improve the customer experience and promote public safety.
Verisk did not acquire the criminal conviction (eLuminateHR.com) or health care cost recovery (MVAreCOUP.com) businesses, which will be owned and operated independently by Safer Public, LLC. | 2021-11-03T00:00:00 | 2021-11-03T00:00:00 | 205.559998 | 208.970001 | 207.970001 | 203.729996 | 201.740005 | 202.369995 | 200.270004 | 199.990005 | 198.809998 | 201.630005 | 203.729996 | 206.740005 | 207.470001 | 206.529999 | 207.75 | 208.369995 | 211.550003 | 210.630005 | 211.039993 | 212.050003 | 211.929993 | 213.139999 | 213.960007 | 212.020004 | 211.320007 | 207.880005 | 209.320007 | 210.270004 | 208.940002 | 209.309998 | 214.289993 | 216.600006 | 214.589996 | 214.910004 | 216.289993 | 213.820007 | 212.990005 | 216.270004 | 218.029999 | 222.600006 | 224.5 | 226.720001 | 230.029999 | 228.529999 | 229.320007 | 228.210007 |
2021-11-02 | VRSK | Verisk Analytics EPS beats by $0.08, beats on revenue | Verisk Analytics (NASDAQ:VRSK): Q3 Non-GAAP EPS of $1.44 beats by $0.08; GAAP EPS of $1.24 beats by $0.08.
Revenue of $759M (+8.0% Y/Y) beats by $1.58M.
Press Release | 2021-11-03T00:00:00 | 2021-11-03T00:00:00 | 205.559998 | 208.970001 | 207.970001 | 203.729996 | 201.740005 | 202.369995 | 200.270004 | 199.990005 | 198.809998 | 201.630005 | 203.729996 | 206.740005 | 207.470001 | 206.529999 | 207.75 | 208.369995 | 211.550003 | 210.630005 | 211.039993 | 212.050003 | 211.929993 | 213.139999 | 213.960007 | 212.020004 | 211.320007 | 207.880005 | 209.320007 | 210.270004 | 208.940002 | 209.309998 | 214.289993 | 216.600006 | 214.589996 | 214.910004 | 216.289993 | 213.820007 | 212.990005 | 216.270004 | 218.029999 | 222.600006 | 224.5 | 226.720001 | 230.029999 | 228.529999 | 229.320007 | 228.210007 |
2021-11-24 | VRSK | Jobless claims are at decades lows; Jefferies picks the best stocks for labor shortages | gguy44/iStock via Getty Images
"On virtually every employment indicator, the US labor market is sizzling hot," Jefferies says.
This morning, the Labor Department reported that weekly jobless claims fell to 199K from 260K, the lowest number since 1969.
While seasonal adjustments mean the numbers will reverse next week, "the trend in claims is clearly falling," Pantheon Macroecomomics says. "Laying off staff is risky when the labor market is so tight, with near-record job openings."
Jefferies equity strategist Sean Darby and quant strategist Kenneth Chan recently issued their 2022 outlook, including investment themes uncorrelated to their broader market forecast.
In a theme entitled "Workers of the World Unite!" they say that job openings and quits rates at record highs while unemployment is still well off cyclical lows is "particularly pertinent."
"Indeed, Jefferies US economics team has highlighted that US strike activity near doubled in October," they write. "One other example of US labor tightness is that the number of job vacancies is outstripping those unemployed."
They remain "favorably disposed" to the S&P 500 Professional Services (SP500-202020) group.
In that group, Jefferies' top picks are Equifax (NYSE:EFX), Leidos (NYSE:LDOS), Nielsen (NYSE:NLSN) and Verisk Analytics (NASDAQ:VRSK).
See how Seeking Alpha's Quant Rating ranks HR and employment services stocks and find more companies with this screen. | 2021-11-25T00:00:00 | 2021-11-26T00:00:00 | 211.550003 | 210.630005 | 211.039993 | 212.050003 | 211.929993 | 213.139999 | 213.960007 | 212.020004 | 211.320007 | 207.880005 | 209.320007 | 210.270004 | 208.940002 | 209.309998 | 214.289993 | 216.600006 | 214.589996 | 214.910004 | 216.289993 | 213.820007 | 212.990005 | 216.270004 | 218.029999 | 222.600006 | 224.5 | 226.720001 | 230.029999 | 228.529999 | 229.320007 | 228.210007 | 225.809998 | 229.160004 | 224.869995 | 219.639999 | 225.869995 | 221.649994 | 221.910004 | 225.440002 | 229.050003 | 224.5 | 226.660004 | 228.940002 | 224.800003 | 228.570007 | 229.199997 | 222.139999 |
2021-12-13 | VRSK | Verisk Analytics goes ex-dividend tomorrow | Verisk Analytics (NASDAQ:VRSK) had declared $0.29/share quarterly dividend, in line with previous.
Payable Dec. 31; for shareholders of record Dec. 15; ex-div Dec. 14.
See VRSK Dividend Scorecard, Yield Chart, & Dividend Growth. | 2021-12-14T00:00:00 | 2021-12-14T00:00:00 | 208.940002 | 209.309998 | 214.289993 | 216.600006 | 214.589996 | 214.910004 | 216.289993 | 213.820007 | 212.990005 | 216.270004 | 218.029999 | 222.600006 | 224.5 | 226.720001 | 230.029999 | 228.529999 | 229.320007 | 228.210007 | 225.809998 | 229.160004 | 224.869995 | 219.639999 | 225.869995 | 221.649994 | 221.910004 | 225.440002 | 229.050003 | 224.5 | 226.660004 | 228.940002 | 224.800003 | 228.570007 | 229.199997 | 222.139999 | 221.309998 | 221.990005 | 223.850006 | 225.529999 | 227.410004 | 228.080002 | 229.300003 | 228.089996 | 228.729996 | 221.660004 | 221.729996 | 214.309998 |
2018-12-13 | VRTX | Vertex Pharma's Orkambi OK'd in Canada for young children | Health Canada approves Vertex Pharmaceuticals' (NASDAQ:VRTX) ORKAMBI (lumacaftor/ivacaftor) for children aged 2-5 years old with cystic fibrosis who harbor two copies of the F508del CFTR mutation.
The FDA approved the expanded use in August. | 2018-12-14T00:00:00 | 2018-12-14T00:00:00 | 169.460007 | 175.190002 | 173.289993 | 174.589996 | 175.229996 | 183.880005 | 180.259995 | 180.550003 | 172.850006 | 170.309998 | 164.580002 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 |
2018-12-17 | VRTX | Vertex Pharmaceuticals CFO bids adieu | Vertex Pharmaceuticals (VRTX
-2.2%) announces that Thomas Graney will resign as Chief Financial Officer (CFO) effective immediately.
Ian F. Smith, Executive VP and Chief Operating officer, assumed the additional role of interim CFO on December 13. | 2018-12-18T00:00:00 | 2018-12-18T00:00:00 | 173.289993 | 174.589996 | 175.229996 | 183.880005 | 180.259995 | 180.550003 | 172.850006 | 170.309998 | 164.580002 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 |
2018-12-18 | VRTX | Vertex Pharma's VX-150 successful in mid-stage neuropathy study | Results from a Phase 2 clinical trial evaluating Vertex Pharmaceuticals' (NASDAQ:VRTX) VX-150 in patients with pain caused by small fiber neuropathy showed a treatment benefit. The study met the primary endpoint of a statistically significant reduction in pain as measured by the change from baseline at week 6 in weekly average pain intensity on a scale called NRS.
On the safety front, VX-150 was generally well-tolerated. The most frequent adverse event was headache (24% of patients in the treatment group versus 12% for placebo).
The company says the trial is the third successful proof-of-concept study supporting Breakthrough Therapy-tagged VX-150, an inhibitor of a sodium ion channel subtype called NaV1.8 that plays a key role in the transmission of pain signals by nerve cells.
A Phase 2 study of VX-150 in patients with pain following bunionectomy (removal of a bunion at the base of the big toe) is underway.
Vertex is developing a range of preclinical pain molecules, the first of which should reach the clinic next year. | 2018-12-19T00:00:00 | 2018-12-19T00:00:00 | 174.589996 | 175.229996 | 183.880005 | 180.259995 | 180.550003 | 172.850006 | 170.309998 | 164.580002 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 |
2018-12-19 | VRTX | Vertex aiming for Orkambi and Symkevi use by NHS in Scotland | With an eye on inclusion in the National Health Service (NHS) formulary in Scotland, Vertex Pharmaceuticals (VRTX
+0.1%) plans to submit ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor), to be used with ivacaftor (KALYDECO), to the Scottish Medicines Consortium for assessment. If accepted for NHS use, patients could have access in 2019.
The company says there are ~900 people in Scotland with cystic fibrosis. | 2018-12-20T00:00:00 | 2018-12-20T00:00:00 | 175.229996 | 183.880005 | 180.259995 | 180.550003 | 172.850006 | 170.309998 | 164.580002 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 |
2018-12-27 | VRTX | Oppenheimer sees 1H19 risk for smid-cap biotech | Oppenheimer says small- to mid-cap biotech stocks could have more downside risk going into the new year after this quarter's pullback while the historically low valuations for large-cap companies could reach the lowest point.
The firm expects underperformance in 1H19 due in part to a negative macro environment.
Analyst Hartaj Singh remains bullish on the sector despite the "rough" three- to five-year stretch.
Favored companies combine sustained earnings and pipeline catalysts: (REGN
-1.9%), (ALXN
-0.8%), (VRTX
-1.1%).
Small-caps with upcoming catalysts: (ATNM
-0.5%), (CATB
+0.8%), (SLS), (SNSS).
Source: Bloomberg First Word. | 2018-12-28T00:00:00 | 2018-12-28T00:00:00 | 170.309998 | 164.580002 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 |
2018-12-31 | VRTX | Vertex ups stake in CRISPR Therapeutics to 10.4% | CRISPR Therapeutics (CRSP
+2.4%) discloses that CTX001 collaboration partner Vertex Pharmaceuticals (VRTX) has increased its stake to 10.4% (~5.4M shares).
CRISPR/Cas9 competitors Editas Medicine (EDIT
+5.9%) and Intellia Therapeutics (NTLA
+2%) are up as well. | 2019-01-01T00:00:00 | 2019-01-02T00:00:00 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 |
2018-12-31 | VRTX | Proteostasis up 8% after hours on successful Phase 1 study of PTI-428 | Proteostasis Therapeutics (NASDAQ:PTI) is up 8% after hours on the heels of its Phase 1 clinical trial evaluating PTI-428 in cystic fibrosis patients on background Kalydeco (ivacaftor) therapy.
The company says the study met the primary (safety and tolerability) and secondary endpoints (pharmacokinetics) but it did not perform exploratory analyses on other measures (efficacy) due to the small number of enrollees.
Related ticker: (NASDAQ:VRTX) | 2019-01-01T00:00:00 | 2019-01-02T00:00:00 | 166.669998 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 |
2019-01-02 | VRTX | Drug makers OK with price inclusion in TV ads if done fairly | Four members of Big Pharma, Pfizer (PFE
-1.6%), Sanofi (SNY
-1.6%), Eli Lilly (LLY
-1.5%) and Johnson & Johnson (JNJ
-0.9%), responding to the federal government's proposed inclusion of prices in TV drug ads generally support the value of increased transparency for patients, but caution that it needs to be done fairly.
They say that including just the list price will confuse patients since most are only responsible for co-payments. Some may not fill prescriptions if they perceive that they will have to pay the full monty (shockingly high in many cases).
J&J says that if list price disclosures are required for drugs, then hospitals, health insurers and pharmacy benefit managers should play by similar rules.
Sanofi was the least supportive, regarding CMS's proposal as "oversimplified" since would fail to grasp the "nuance and complexity" of prescription drugs and biologics.
The trade association, Pharmaceutical Research and Manufacturers of America (PhRMA), has proposed its own voluntary guidelines that will take effect in April. It prefers to link drug price information to ads and wants to partner with advocacy groups on an online patient affordability platform that will allow them to access information on insurance coverage, co-payments and other factors in addition to drug prices.
The 60-day comment period ended last month. CMS will now decide on the specific regulation. Legal challenges are a near certainty if prices are required in advertisements.
Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, XBI, VHT, IYH, RYH, IBB, XHE, PJP, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, ESRX, WBA, CVS, UNH, CELG, LLY, CI | 2019-01-03T00:00:00 | 2019-01-03T00:00:00 | 165.110001 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 |
2019-01-03 | VRTX | Vertex teams up with Arbor Biotech in gene-editing therapies | Vertex Pharmaceuticals (NASDAQ:VRTX) will collaborate with Arbor Biotechnologies to discover novel proteins for gene-editing therapies for cystic fibrosis and four other yet-to-be-named diseases. The partnership will leverage Arbor's protein biodiscovery platform based on machine learning, genome sequencing, gene synthesis and high-throughput screening.
The specific focus will be on programmable DNA endonucleases with high fidelity and catalytic activity.
VRTX will pay Arbor an upfront amount, research funding, milestones and royalties on net sales. Specific financial terms are not disclosed. | 2019-01-04T00:00:00 | 2019-01-04T00:00:00 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 |
2019-01-03 | VRTX | BMY/Celgene tie-up buoys Gilead and Vertex premarket | Gilead Sciences (NASDAQ:GILD) is up 3% and Alexion Pharmaceuticals (NASDAQ:VRTX) is up 1% premarket, albeit both on modest volume, on the heels of Bristol-Myers Squibb's $74B bid for fellow biotech Celgene. | 2019-01-04T00:00:00 | 2019-01-04T00:00:00 | 161.070007 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 |
2019-01-04 | VRTX | Biotechs lead broad market advance, XBI up 5% | Biotech and healthcare companies are enjoying robust buying in conjunction with the broad market. The SPDR S&P Biotech ETF (XBI
+5.1%) is ahead of the major indexes, albeit on below-average volume.
Selected tickers: (XLV
+3.5%)(BIB
+10.7%)(PJP
+3.7%)(VHT
+3.8%)(IYH
+3.7%)(IBB
+5.4%)(OTCQX:RHHBY
+1.1%)(ABBV
+3.1%)(AGN
+4.7%)(AZN
+2.6%)(BMY
+4.9%)(MRK
+3.2%)(NVS
+1.8%)(BHC
+5.1%)(TEVA
+6.1%)(BIIB
+5.2%)(AMGN
+3.7%)(GILD
+4.3%)(CELG
+6.2%)(VRTX
+5.3%)(XTLB
+10.4%)(VTL
+18.4%)(SNDX
+16.9%)(SPHS
+24.3%)(SCYX
+15.2%)(RETA
+12.8%)(PBYI
+3.2%)(HSGX
+23.9%)(FLKS
+47.1%)(DRRX
+26.1%)(CDTX
+10.4%)(CTIC
+28.8%)(BPTH
+19.6%)(AKAO
+44.9%)(FLGT
+19%)(CRSP
+10.1%)(KRYS
+12.1%) | 2019-01-05T00:00:00 | 2019-01-07T00:00:00 | 159.759995 | 160.25 | 160.389999 | 167.399994 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 |
2019-01-10 | VRTX | Drug applications take back seat to safety surveillance at FDA during shutdown | In a tweet, FDA Commissioner Scott Gottlieb, M.D. says the agency is having to shift resources from premarket drug review work to safety surveillance during the federal government shutdown as President Trump and congressional leaders squabble over the border wall. Drug firms will, no doubt, notify their lobbyists on this development.
Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY | 2019-01-11T00:00:00 | 2019-01-11T00:00:00 | 175.449997 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 |
2019-01-11 | VRTX | Dem lawmakers introduce bill to lower U.S. drug prices | On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices.
Their bill, similar to the Trump administration's idea to benchmark U.S. drug prices to Europe's, would create an "international pricing index" as a means to more closely align the U.S. with other countries.
It would also allow the Secretary of Health and Human Services (HHS) to negotiate prices under Medicare Part D and allow Americans to purchase medicines from Canada and other countries.
Predictably, the Pharmaceutical Research and Manufacturers of America, the industry's top lobbying organization, is opposed, saying the bill would "interfere with patient access to medicine while also undermining the U.S. intellectual property system, replicating the flawed policies of foreign governments and circumventing the FDA's robust safety standards."
Drugmakers blame pharmacy benefit managers (PBMs) for the problem saying they continue to demand ever-increasing rents for inclusion on formularies.
Several drugmakers maintained prices for a short while last year, but reinstituted increases this month on more than 250 medications, including top seller Humira at AbbVie. On the plus side, the increases were more modest, with almost all being less than 10%.
Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, ABC, CAH, MCK, UNH, CVS, ESRX | 2019-01-12T00:00:00 | 2019-01-14T00:00:00 | 178.380005 | 179.449997 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 |
2019-01-15 | VRTX | FDA Commish touts advances/successes | In a stream of tweets, FDA Commissioner Scott Gottlieb, M.D. details a number of accomplishments and advances by the agency. Highlights:
Federal government shutdown: About 400 (or 410) staffers are returning to work to conduct key inspections: ~150 in food, ~100 in high-risk medical device manufacturing, ~70 in high-risk drug manufacturing and ~90 in high-risk biologic manufacturing. They plan to work without pay this week.
Generics and biosimilar programs will be negatively impacted if the shutdown persists. Carryover fees are funding the work at present. Higher-risk products are being prioritized.
Seven biosimilars were approved in 2018, raising the cumulative total to 16. 70 programs are in process.
Five generic drugs were approved last year under the new competitive generic therapy designation (accelerated revenue and 180 days of market exclusivity). "First generics" comprised almost 10% of the 971 generic drug applications approved in fiscal 2018 (no prior generic was on the market). The total number of approvals was a record for the agency. 1,021 were approved in calendar 2018.
Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, PRGO, MYL, MNK, RDY, AKRX | 2019-01-16T00:00:00 | 2019-01-16T00:00:00 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 |
2019-01-16 | VRTX | Hospitals squeezed by high drug costs | A study funded by the American Hospital Association, Federation of American Hospitals and the American Society of Health-System Pharmacists found that total drug spend per hospital admission rose 18.5% between 2015 and 2017, adding $1.8M in additional costs for an average hospital.
Outpatient drug spending per admission rose almost 30% while inpatient spending for medicines rose 10%. Price hikes as high as 80% or more occurred in anesthetics, parenteral solutions, opioid agonists and chemo.
More than 90% of hospitals surveyed had to identify alternative therapies to mitigate the impact of price increases and drug shortages. One in four had to downsize staff.
The price of Roche's stroke med Activase increased 19% to $4,143. Johnson & Johnson's Remicade, AbbVie's Humira and Amgen's Enbrel increased between 15 - 21%.
The majority of hospitals reported that competition had little effect on prices. Two of the 10 most expensive drugs in fiscal 2017 had generic or biosimilar alternatives enter the market in 2016, but the two still increased 4.1%, albeit more modestly than the 14.4% average hike among the other eight.
About 750 hospitals have joined a non-profit venture called Civica Rx aimed at managing drug costs and supply.
XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY
 | 2019-01-17T00:00:00 | 2019-01-17T00:00:00 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 |
2019-01-15 | VRTX | FDA to beef up cell and gene therapy staff | Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 such therapies per year by 2025.
50 new clinical reviewers will be added (certainly contingent on the resolution of the federal government impasse between President Trump and Congress).
New policy guidance will be issued this year. The agenda includes working with sponsors to make maximum use of accelerated programs, including regenerative medicine advanced therapy (RMAT)Â designation, a series of clinical guidance documents to inform product development, including gene therapies for blood disorders, and how to use the accelerated approval pathway in cases where the gene therapy addresses the underlying genetic defect.
The guidance will also include information designed to help in the development of CAR-T therapies (and other cellular products) and to promote a better understanding of the critical factors in manufacturing with the goal of allowing minor manufacturing changes without requiring new bridging studies.
Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, XON, ALNY, CLLS, SRNE, ZIOP, CYAD, BLUE, NTLA, CRSP, EDIT, SRPT, SLDB, RCKT, RGNX, BGNE, SGMO, ONCE, VYGR | 2019-01-16T00:00:00 | 2019-01-16T00:00:00 | 180.789993 | 184.649994 | 177.929993 | 179.610001 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 |
2019-01-22 | VRTX | Expanded use of Vertex Pharma's Orkambi OK'd in Europe | The European Commission has approved the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) ORKAMBI (lumacaftor/ivacaftor) for children ages 2 - 5 years old with cystic fibrosis who have two copies of the F508del mutation. It was previously approved for children at least six years old who have two copies of the mutation. | 2019-01-23T00:00:00 | 2019-01-23T00:00:00 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 |
2019-01-22 | VRTX | Editas and CRISPR weigh on biotechs, XBI down 3% | The broad market's down day notwithstanding, biotechs are getting drubbed, led by Editas Medicine and CRISPR Therapeutics. The SPDR S&P Biotech ETF (XBI
-2.9%) is down, albeit on average volume.
Selected tickers: (IONS
-1.5%)(FPRX
-2.3%)(GBT
-2.4%)(INCY
-1.5%)(UTHR
-2.1%)(PBYI
-2.9%)(NKTR
-3.6%)(EXAS
-3.4%)(BPMC
-2.8%)(BMRN
-2%)(CLVS
-2.6%)(CELG
-1.5%)(GLPG
-0.8%)(BGNE
-3.6%)(ALKS
-3.2%)(ALNY
-3.8%)(VRTX
-0.6%)(GILD
-0.8%)(BIIB
-0.2%)(AMGN
-0.8%) | 2019-01-23T00:00:00 | 2019-01-23T00:00:00 | 172.210007 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 |
2019-01-24 | VRTX | Vertex announces departure of Ian Smith, Names interim CFO | Vertex (NASDAQ:VRTX
-0.7%) says that Ian Smith has been terminated as COO and Interim CFO, effective immediately.
Paul Silva, Senior Vice President and the Companyâs Corporate Controller and Chief Accounting Officer since 2008, has been appointed interim CFO.
Press Release | 2019-01-25T00:00:00 | 2019-01-25T00:00:00 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 |
2019-01-23 | VRTX | Vertex boots COO over "personal behavior" | Vertex Pharmaceuticals (NASDAQ:VRTX) has fired COO and CFO Ian Smith over "personal behavior that violated Vertex's Code of Conduct."
Corporate Controller and Chief Accounting Officer Paul Silva will take over the CFO job on an interim basis until a permanent successor is appointed.
Shares are down 1% after hours. | 2019-01-24T00:00:00 | 2019-01-24T00:00:00 | 173.779999 | 173.229996 | 175.449997 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 |
2019-01-28 | VRTX | Expanded use for Vertex's Kalydeco OK'd in Canada | Health Canada approves the use of Vertex Pharmaceuticals' (NASDAQ:VRTX
-0.7%) KALYDECO (ivacaftor) to include children with cystic fibrosis ages 12 to <24 months who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
The FDA approved the expanded label in August 2018, followed by EMA approval in Europe three months later. | 2019-01-29T00:00:00 | 2019-01-29T00:00:00 | 173.419998 | 170.059998 | 166.169998 | 163.429993 | 158.660004 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 |
2019-02-04 | VRTX | Vertex Pharmaceuticals Q4 2018 Earnings Preview | Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q4 earnings results on Tuesday, February 5th, after market close.
The consensus EPS Estimate is $1.06 (+73.8% Y/Y) and the consensus Revenue Estimate is $820.13M (+25.9% Y/Y).
Over the last 2 years, VRTX has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 75 days, EPS estimates have seen 5 upward revisions and 3 downward. Revenue estimates have seen 4 upward revisions and 1 downward. | 2019-02-05T00:00:00 | 2019-02-05T00:00:00 | 161.300003 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 |
2019-02-06 | VRTX | B. Riley sees 144% upside for Genfit in premarket analyst action | Genfit SA (OTCPK:GNFTF) initiated with Buy rating and a â¬46 (144% upside) price target at B. Riley FBR citing an expected positive outcome from the Phase 3 RESOLVE-IT study evaluating elafibranor in NASH.
CymaBay Therapeutics (NASDAQ:CBAY) initiated with Neutral rating with a $9 (flat) price target at B. Riley FBR citing valuation.
Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Hold at Maxim Group citing valuation. Shares up 4% premarket after Q4 results released after the close yesterday. | 2019-02-07T00:00:00 | 2019-02-07T00:00:00 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 |
2019-02-05 | VRTX | Vertex Q4 non-GAAP earnings up 113%; shares up 2% after hours | Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 results ($M): Revenues: 870.1 (+33.5%); product revenues: 868.2 (+39.8%).
Key product sales: Kalydeco: 259 (+1.2%); Orkambi: 315 (-13.7%); Symdeko: 294.
Net income: 1,550.5 (+999%) - increase due to $1.5B income tax benefit. Non-GAAP net income: 336.9 (+113.4%).
EPS: $5.97 (+999%); non-GAAP EPS: 1.30 (+113.1%).
2019 guidance: CF product revenues: $3.45B - 3.55B.
Previously: Vertex Pharmaceuticals beats by $0.24, beats on revenue (Feb. 5) | 2019-02-06T00:00:00 | 2019-02-06T00:00:00 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 |
2019-02-05 | VRTX | Vertex Pharmaceuticals beats by $0.24, beats on revenue | Vertex Pharmaceuticals (NASDAQ:VRTX): Q4 Non-GAAP EPS of $1.30 beats by $0.24; GAAP EPS of $5.97 beats by $5.29.
Revenue of $869.4M (+39.6% Y/Y) beats by $49.27M.
Press Release | 2019-02-06T00:00:00 | 2019-02-06T00:00:00 | 156.5 | 151.910004 | 161.839996 | 162.369995 | 161.419998 | 165.710007 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 |
2019-02-14 | VRTX | Vertex's tezacaftor/ivacaftor successful in late-stage CF study in young kids | A Phase 3 clinical trial conducted in Europe and Australia evaluating the combination of Vertex Pharmaceuticals' (NASDAQ:VRTX
-0.2%) tezacaftor and ivacaftor in children aged 6 - 11 years with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one residual function mutation met the primary endpoint.
The data showed that treatment with the combination produced a statistically significant improvement in lung function, measured by the absolute change in lung clearance index, compared to placebo.
The combination, branded as Symdeko (tezacaftor/ivacaftor and ivacaftor), is currently approved in the U.S. and Europe for CF patients at least 12 years old. The company submitted its U.S. marketing application for the expanded patient population last quarter. It expects to file its application in Europe in H2. | 2019-02-15T00:00:00 | 2019-02-15T00:00:00 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 |
2019-02-13 | VRTX | Vertex files for mixed shelf offering | Vertex Pharmaceuticals (NASDAQ:VRTX) has filed a prospectus for an unspecified mixed shelf offering. | 2019-02-14T00:00:00 | 2019-02-14T00:00:00 | 164.080002 | 163.729996 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 |
2019-02-15 | VRTX | FDA creates new accelerated review pathway for generic drug applications | In a statement, FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient populations and/or are difficult to copy due to their complexity.
The designation, called Competitive Generic Therapies (CGT), provides for more intensive FDA guidance on development as well as a shorter review clock. An approved abbreviated new drug application (ANDA) for a CGT-tagged generic medicine will also enjoy a 180-day period of market exclusivity (no real change here since this is the same exclusivity period for an approved "first-to-file" application).
Dr. Gottlieb says the agency has signed off on 100 CGT requests to date with five ANDAs approved in 2018 (August - December).
Selected tickers: XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, PFE, CELG, LLY, GNRX, PRGO, MYL, LCI, AKRX, MNK, RDY | 2019-02-16T00:00:00 | 2019-02-19T00:00:00 | 172.699997 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 |
2019-02-19 | VRTX | Maryland strikes out in reviving drug price-gouging law | The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce.
A trade group representing generic drugmakers filed the legal challenge to the law.
Maryland's law, enacted in 2017 after high-profile price hikes by certain pharma firms, including Turing Pharmaceuticals with Daraprim, prohibited "unconscionable" price increases for essential off-patent medicines or generics sold there.
XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, PRGO, MYL, RDY, AKRX | 2019-02-20T00:00:00 | 2019-02-20T00:00:00 | 175.850006 | 178.190002 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 |
2019-02-21 | VRTX | Biotechs under pressure, XBI down 1.4% | Biotechs can't find any love this morning. The SPDR S&P Biotech ETF (XBI
-1.4%) is down, albeit on below-average volume. Recent action is a bit negative, including modest pressure on Celgene (CELG
-1.3%) related to merger rumors, Biogen (BIIB
-3.7%) after a Stifel downgrade and some soft earnings and/or guidance.
Selected tickers: (IONS
-1.5%)(GBT
-0.7%)(INCY
-1.5%)(CRSP
-3.4%)(EDIT
-3.5%)(NTLA
-7.4%)(XON
-0.9%)(UTHR
-0.1%)(SAGE
-0.8%)(REGN
-0.8%)(PBYI
-0.9%)(NKTR
-4.7%)(EXAS
-1.6%)(BPMC
-4%)(CLVS
-0.9%)(GLPG
-1.9%)(BLUE
-3.1%)(BGNE
-1.1%)(ALKS
-1.8%)(ALXN
-2.3%)(VRTX
-1.6%)(GILD
-1.6%)(AMGN
-0.8%) | 2019-02-22T00:00:00 | 2019-02-22T00:00:00 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 |
2019-02-21 | VRTX | U.S. healthcare spending to rise 5.5% per annum over next decade | According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP).
Medicare spending is expected to rise 7.4% per annum over the same period, above 5.5% for Medicaid and 4.8% for private insurance plans.
Medicare enrollment should peak at 2.9% this year.
Prescription drug spending is forecasted to rise 5.6% per year between 2018 and 2027 as is hospital spending.
By 2027, federal, state and local governments are projected to fund 47% of national healthcare spending (45% in 2017).
Selected tickers: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, IBB, XBI, XPH, IHE, PPH, VHT, OTCQX:RHHBY, ABBV, AGN, AZN, BMY, GSK, JNJ, MRK, NVS, BHC, TEVA, AMGN, BIIB, GILD, VRTX, TAK, ESRX, WBA, CVS, UNH, PFE, CELG, LLY, CI, CNC, HUM, HCA, ANTM, UNH, CVS, WCG, MOH | 2019-02-22T00:00:00 | 2019-02-22T00:00:00 | 182.300003 | 186.029999 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 |
2019-02-25 | VRTX | First patient dosed in study of gene therapy CTX001 in beta thalassemia | CRISPR Therapeutics (NASDAQ:CRSP) and development partner Vertex Pharmaceuticals (NASDAQ:VRTX) announce that the first beta thalassemia patient has been dosed with CTX001, a gene therapy based on the CRISPR/Cas9 gene editing approach.
The patient is enrolled in a Phase 1/2 study evaluating CTX001 in patients with hemoglobin disorders. The first sickle cell disease subject should be dosed by mid-year.
CRSP is up 11% premarket, stoked by Roche's bid for Spark Therapeutics. | 2019-02-26T00:00:00 | 2019-02-26T00:00:00 | 188.160004 | 183.910004 | 186.679993 | 186.149994 | 190.520004 | 194.699997 | 193.880005 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 |
2019-03-06 | VRTX | Biotechs remain under pressure on Gottlieb exit | Investors are avoiding biotechs in the wake of the abrupt resignation notice from FDA Commissioner Scott Gottlieb, M.D. who was a champion of more efficient and responsive agency action, although punters should expect another industry-friendly chief from the Trump administration.
Selected tickers: SPDR S&P Biotech ETF (XBI
-2.9%), Biogen (BIIB
-1.8%), Amgen (AMGN
-3%), Intrexon (XON
-2.4%), Ionis Pharmaceuticals (IONS
-2.4%), Nektar Therapeutics (NKTR
-4.2%), Gilead Sciences (GILD
-2%), Clovis Oncology (CLVS
-4.3%), Vertex Pharmaceuticals (VRTX
-2.6%), bluebird bio (BLUE
-2.7%), BioMarin Pharmaceutical (BMRN
-1.2%) | 2019-03-07T00:00:00 | 2019-03-07T00:00:00 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 |
2019-03-06 | VRTX | Vertex's VX-445 triple combo successful in two late-stage CF studies | Vertex Pharmaceuticals (NASDAQ:VRTX) announces positive outcomes from two Phase 3 clinical trials evaluating the combination of next-generation corrector VX-445, tezacaftor and ivacaftor in cystic fibrosis (CF) patients.
In the trial with CF patients with one F508del mutation and one minimal function mutation, treatment with the triple combo produced a mean absolute improvement in lung function of 13.8% (measured by ppFEV1) at week 4 compared to placebo (p<0.0001).
In the trial with CF patients with two F508del mutations, ppFEV1 improved 10.0% at week 4 compared to control (p<0.0001).
The company says the results are similar to the triple combination of VX-659, tezacaftor and ivacaftor that were reported in Q4 2018 with a similar safety profile. It will assess 24-week data, expected next quarter, before selecting the best regimen for global marketing applications. It expects to file its application in the U.S. in Q3 followed by Europe in Q4.
CF is caused by mutations in the CFTR gene which prevents the CFTR protein from being made correctly, leading to an imbalance of salt and fluids inside and outside of cells. A corrector molecule helps the CFTR protein form the right shape so that it is able to move to the cell surface allowing chloride to pass out of the cell, reducing CF symptoms. | 2019-03-07T00:00:00 | 2019-03-07T00:00:00 | 189.889999 | 186.580002 | 189.5 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 |
2019-03-12 | VRTX | Biotechs (mostly) in the green on Sharpless nod to head FDA | Biotech investors appear to be comfortable with FDA Commissioner designee Norman Sharpless who has run the NCI since 2017.
Selected tickers: Ionis Pharmaceuticals (IONS
+0.7%), Incyte (INCY
+0.8%), Intrexon (XON
+3.4%), CRISPR Therapeutics (CRSP
+1.4%), Editas Medicine (EDIT
+2.6%), Intellia Therapeutics (NTLA
+1.3%), bluebird bio (BLUE
-0.5%), BioMarin Pharmaceutical (BMRN
+1.4%), Vertex Pharmaceuticals (VRTX
+1.1%), Amgen (AMGN), Gilead Sciences (GILD
+0.7%), Biogen (BIIB
+0.7%), Galapagos N.V. (GLPG
-0.5%), Alexion Pharmaceuticals (ALXN
+1.6%), Alnylam Pharmaceuticals (ALNY
+0.1%) | 2019-03-13T00:00:00 | 2019-03-13T00:00:00 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 |
2019-03-12 | VRTX | Vertex's Symdeko OK'd in Australia | The Australian Therapeutic Goods Administration approves Vertex Pharmaceuticals' (NASDAQ:VRTX) SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of patients with cystic fibrosis (CF) at least 12 years old who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor.
Reimbursement will be considered at this month's meeting of the Pharmaceutical Benefits Advisory Committee. | 2019-03-13T00:00:00 | 2019-03-13T00:00:00 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 |
2019-03-11 | VRTX | Sickle cell players in the green after 60 Minutes piece | Biotechs developing gene therapies for sickle cell disease are seeing a modest uptick in buying after a 60 Minutes segment last night on the preliminary success of an unnamed gene therapy. The patient who was the primary focus appeared to have completely responded and she has been pain-free from vaso-occlusive crises since receiving the one-time treatment.
Selected tickers: bluebird bio (BLUE
+4.8%), CRISPR Therapeutics (CRSP
+3%), Vertex Pharmaceuticals (VRTX
+1.4%), Editas Medicine (EDIT
+3.8%) | 2019-03-12T00:00:00 | 2019-03-12T00:00:00 | 188.089996 | 186.380005 | 187.050003 | 190.910004 | 191.520004 | 187.979996 | 187.020004 | 182.389999 | 180.179993 | 181.339996 | 181.529999 | 184.009995 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 |
2019-03-27 | VRTX | Eloxx Pharma up 2% on encouraging ELX-02 data | Thinly traded micro cap Eloxx Pharmaceuticals (NASDAQ:ELOX
+1.7%) is up on below-average volume on the heels of encouraging preclinical data on lead candidate ELX-02 in cystic fibrosis (CF). The results were presented at the ECFS Basic Science Conference in Croatia.
The company says small molecule ELX-02 significantly increased CFTR protein expression in organoids derived from CF patients (CF is caused by mutations in the CFTR gene which causes the deficiency/absence of the CFTR protein).
Eloxx plans to launch a Phase 2 study in the U.S. and Europe this year in CF patients carrying at least one G542X mutation, adding that it expects to report topline results this year as well.
ELX-02 is a eukaryotic ribosomal selective glycoside, a compound that modulates the ribosome, a part of the cell that plays a major role in protein production. It is designed to increase the read-through activity in patients with nonsense mutations, enabling the production of enough full-length protein to restore biochemical activity.
CF-related tickers: Proteostasis Therapeutics (PTI -7.9%); Vertex Pharmaceuticals (NASDAQ:VRTX
-0.6%) | 2019-03-28T00:00:00 | 2019-03-28T00:00:00 | 185.25 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 |
2019-03-28 | VRTX | British CF patients still waiting for routine access to Vertex's Orkambi | Despite European Commission approval in November 2015, cystic fibrosis (CF)Â patients in Britain still do not have routine access to Vertex Pharmaceuticals' (VRTX
-1.6%) ORKAMBI (lumacaftor/ivacaftor) due to an impasse over the price with the Institute for Health and Care Excellence (NICE), the cost and care quality advisor to the National Health Service (NHS).
The company recently destroyed almost 8,000 packs of expired product that was earmarked for the EU, including the UK.
Last year, British health officials offered £500M over five years and £1B over 10 years for NHS access to all of the company's CF drugs but the company stiff-armed the proposal as inadequate citing the substantial cost to develop the meds.
CEO Jeff Leiden, M.D., Ph.D. and CCO Stuart Arbuckle recently appeared before a Parliamentary committee to answer questions on the issue. Dr. Leiden subsequently met with Health Secretary Matt Hancock who told the House of Commons that "constructive" discussions are continuing.
About 600 British CF patients have received ORKAMBI through a special access program. | 2019-03-29T00:00:00 | 2019-03-29T00:00:00 | 185.720001 | 188.070007 | 186.860001 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 |
2019-04-02 | VRTX | New finance chief at Vertex | Vertex Pharmaceuticals (NASDAQ:VRTX) appoints Charles Wagner as EVP and CFO effective April 10. He joins the firm from Ortho Clinical Diagnostics where he was CFO and EVP, Finance. | 2019-04-03T00:00:00 | 2019-04-03T00:00:00 | 187.839996 | 183.059998 | 185.759995 | 186.330002 | 188.919998 | 189.809998 | 188.75 | 192.160004 | 190.039993 | 187.800003 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 |
2019-04-16 | VRTX | CRISPR and Vertex's CTX001 Fast Track'd for beta thalassemia | The FDA designates CRISPR Therapeutics (NASDAQ:CRSP) and development partner Vertex Pharmaceuticals' (NASDAQ:VRTX) gene therapy candidate CTX001 for Fast Track review for the treatment of transfusion-dependent beta thalassemia.
A Phase 1/2 open-label study launched in February.
CTX001 is also Fast Track-tagged for sickle cell disease. The first patient should be infused mid-year.
Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
CRSP is up 4% premarket on light volume. | 2019-04-17T00:00:00 | 2019-04-17T00:00:00 | 181.110001 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 |
2019-04-17 | VRTX | Drugmaker selloff intensifies on D.C. pricing headwinds | Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem.
The SPDR S&P Biotech ETF (XBI
-4.6%) is down on almost 75% higher volume while the SPDR S&P Pharmaceuticals ETF (XPH
-3.2%) is down on almost 33% higher volume (albeit on turnover of only 72K shares). Johnson & Johnson (JNJ
+1.4%) is the only one above water.
Selected tickers: Biogen (BIIB
-1%); Amgen (AMGN
-2.2%); AbbVie (ABBV
-2.7%); Allergan (AGN
-4.1%); Bristol-Myers Squibb (BMY
-0.7%); Merck (MRK
-3%); Eli Lilly (LLY
-2.5%); Pfizer (PFE
-2.4%); Teva Pharmaceutical Industries (TEVA
-3.2%); GlaxoSmithKline (GSK
-0.4%); Novartis (NVS
-2.2%); AstraZeneca (AZN
-0.7%); Bausch Health (BHC
-3.4%); Vertex Pharmaceuticals (VRTX
-5.3%); Gilead Sciences (GILD
-1.7%); Seattle Genetics (SGEN
-5%); CRISPR Therapeutics (CRSP
-8.1%); Editas Medicine (EDIT
-5.6%); Intellia Therapeutics (NTLA
-7.9%); Regeneron Pharmaceuticals (REGN
-5%); Incyte (INCY
-3.1%); Intrexon (XON
-10.7%); Alexion Pharmaceuticals (ALXN
-7.1%); BioMarin Pharmaceutical (BMRN
-6%) | 2019-04-18T00:00:00 | 2019-04-18T00:00:00 | 178.610001 | 177.259995 | 180.520004 | 182.570007 | 185.660004 | 186.110001 | 188.089996 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 |
2019-04-30 | VRTX | FDA OKs expanded use of Vertex's Kalydeco | Vertex Pharmaceuticals (NASDAQ:VRTX) announces that the FDA has approved KALYDECO (ivacaftor) for the treatment of children as young as six months old with cystic fibrosis who have at least one mutation in the CFTR gene.
Previously, the product was approved for use in kids as young as 12 months old.
Shares are up a fraction premarket. | 2019-05-01T00:00:00 | 2019-05-01T00:00:00 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 |
2019-04-29 | VRTX | Vertex Pharmaceuticals Q1 2019 Earnings Preview | Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q1 earnings results on Tuesday, April 30th, after market close.
The consensus EPS Estimate is $1.01 (+32.9% Y/Y) and the consensus Revenue Estimate is $853M (+33.1% Y/Y).
Over the last 2 years, vrtx has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 6 upward revisions and 7 downward. Revenue estimates have seen 5 upward revisions and 3 downward. | 2019-04-30T00:00:00 | 2019-04-30T00:00:00 | 187.479996 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 |
2019-04-30 | VRTX | Vertex posts healthy Q1; revenues up 34%; earnings up 28% | Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 results ($M): Revenues: 858.4 (+34.0%); product sales: 857.3 (+34.4%).
Key product sales: Symdeco/Symkevi: 320 (+841.2%); Orkambi: 293 (-17.2%); Kalydeco: 244 (-2.4%).
Net income: 269 (+28.1%); non-GAAP net income: 296 (+51.0%); EPS: 1.03 (+27.2%); non-GAAP EPS: 1.14 (+50.0%).
2019 guidance: Product sales: $3.45B - 3.55B (unch).
Previously: Vertex Pharmaceuticals beats by $0.13, beats on revenue (April 30) | 2019-05-01T00:00:00 | 2019-05-01T00:00:00 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 |
2019-04-30 | VRTX | Vertex Pharmaceuticals beats by $0.13, beats on revenue | Vertex Pharmaceuticals (NASDAQ:VRTX): Q1 Non-GAAP EPS of $1.14 beats by $0.13; GAAP EPS of $1.03.
Revenue of $858.44M (+34.0% Y/Y) beats by $5.44M.
Press Release | 2019-05-01T00:00:00 | 2019-05-01T00:00:00 | 181.759995 | 179.979996 | 182.559998 | 181.529999 | 183.850006 | 189.910004 | 185.820007 | 182.419998 | 183.949997 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 |
2019-05-13 | VRTX | FDA finalizes guidance on interchangeable biosimilars | The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off.
None has been approved in the U.S. yet, but Boehringer Ingelheim is working on interchangeability status for its biosimilar to AbbVie's (NYSE:ABBV) Humira (adalimumab). Interchangeable insulin products should coming in the next few years.
A key requirement of the new guidelines is a "switching study" aimed at demonstrating that alternating between the biosimilar and branded product does not impact safety or efficacy.
ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA
Selected tickers: Biogen (NASDAQ:BIIB); Amgen (NASDAQ:AMGN); Vertex Pharmaceuticals (NASDAQ:VRTX); Gilead Sciences (NASDAQ:GILD); Takeda (NYSE:TAK); Bausch Health (NYSE:BHC); Roche (OTCQX:RHHBY); Allergan (NYSE:AGN); AstraZeneca (NYSE:AZN); Bristol-Myers Squibb (NYSE:BMY); GlaxoSmithKline (NYSE:GSK); Johnson & Johnson (NYSE:JNJ); Eli Lilly (NYSE:LLY); Merck (NYSE:MRK); Novo Nordisk (NYSE:NVO); Novartis (NYSE:NVS); Pfizer (NYSE:PFE); Teva Pharmaceutical Industries (NYSE:TEVA) | 2019-05-14T00:00:00 | 2019-05-14T00:00:00 | 186.050003 | 187.110001 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 |
2019-05-15 | VRTX | Vertex teams up with Kymera to advance small molecule protein degraders | Vertex Pharmaceuticals (NASDAQ:VRTX) inks a four-year R&D collaboration agreement with privately held Kymera Therapeutics aimed at advancing therapies called protein degraders against a range of targets.
The partnership will leverage Kymera's Pegasus drug discovery platform with Vertex's scientific, clinical and regulatory know-how to accelerate the development of a line-up of drugs for serious diseases.
Kymera says targeted protein degraders are bifunctional small molecules that can theoretically target "undruggable" and "difficult-to-drug" proteins via harnessing the body's natural cellular processes to eliminate disease-causing proteins.
Under the terms of the deal, VRTX will pay Kymera $70M upfront, up to $1B in potential milestones for up to six programs and tiered royalties on net sales. | 2019-05-16T00:00:00 | 2019-05-16T00:00:00 | 187.889999 | 184.149994 | 188.889999 | 188.929993 | 188.309998 | 190.369995 | 185.119995 | 182.779999 | 182.490005 | 179.740005 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 |
2019-05-30 | VRTX | Vertex selects triple CF combo for global regulatory filings | Vertex Pharmaceuticals (NASDAQ:VRTX) has selected the combination of elexacaftor (VX0445), tezacaftor and ivacaftor as its new cystic fibrosis (CF) therapy for patients at least 12 years old with one F508del mutation and one minimal function mutation and in those with two F508del mutations.
Elexacaftor is a next-generation corrector while tezacaftor and ivacaftor are the active ingredients in SYMDEKO.
It plans to file its U.S. marketing application next quarter followed by an application in Europe in Q4. | 2019-05-31T00:00:00 | 2019-05-31T00:00:00 | 166.970001 | 168.160004 | 168.520004 | 175.369995 | 172.580002 | 174.610001 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 |
2019-06-07 | VRTX | Elox Pharma up 34% on positive data on lead CF candidate | Thinly traded micro cap Eloxx Pharmaceuticals (NASDAQ:ELOX
+33.9%) is up on a 6x surge in volume, albeit on only 179K shares, in reaction to new data on lead candidate ELX-02, in Phase 2 development for cystic fibrosis (CF) and cystinosis. The results were presented at the European Cystic Fibrosis Society Conference in Liverpool.
Studies showed that ELX-02 increased/restored functional CFTR protein in a dose-dependent manner and increased CFTR messenger RNA (mRNA) to healthy control levels.
It also demonstrated a favorable safety profile with high (98%) bioavailability via subcutaneous injection.
ELX-02Â is a eukaryotic ribosomal selective glycoside, a compound that modulates the ribosome, a part of the cell that plays a major role in protein production. It is designed to increase the read-through activity in patients with nonsense mutations, enabling the production of enough full-length protein to restore biochemical activity.
CF is caused by the absence or dysfunction of a protein called CFTR that controls the movement of salt and water in an out of cells. The cause of the absence or dysfunction of the protein is genetic mutations in the gene that encodes CFTR.
CF-related tickers: Vertex Pharmaceuticals (NASDAQ:VRTX
-2.7%), Proteostasis Therapeutics (PTI -4.5%), Corbus Pharmaceuticals (NASDAQ:CRBP
+1.5%) | 2019-06-08T00:00:00 | 2019-06-10T00:00:00 | 172.850006 | 172.520004 | 168.979996 | 172.600006 | 169.539993 | 173.869995 | 174.759995 | 170.279999 | 169.009995 | 169.910004 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 |
2019-06-21 | VRTX | FDA approves expanded indication of Symdeko for cystic fibrosis | Vertex Pharmaceuticals (NASDAQ:VRTX
+0.9%) says it received Food and Drug Administration approval of its Symdeko (tezacaftor/ivacaftor and ivacaftor) tablets for treatment of pediatric patients with cystic fibrosis aged 6-11 who have certain genetic mutations.
VRTX says a Phase 3 study of Symdeko in children 6-11 showed the regimen was generally well tolerated with safety data similar to previous studies of patients aged 12 years and older.
Symdeko already was approved by the FDA for the treatment of cystic fibrosis in patients 12 years and older with certain mutations, and an additional dosage strength of the tablet is now available in connection with this approval. | 2019-06-22T00:00:00 | 2019-06-24T00:00:00 | 168.850006 | 164.610001 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 |
2019-06-25 | VRTX | Pharma players in green on AbbVie/Allergan deal | Members of Big Biopharma, with the notable exception of AbbVie, are all enjoying a spike in buying after its $63B bid for Allergan, stoking hopes that big healthcare mergers are back in play.
Selected tickers: Takeda (TAK
+1.3%), Bausch Health Companies (BHC
+4.2%), Roche (OTCQX:RHHBY
+0.2%), AstraZeneca (AZN
+0.2%), Bristol-Myers Squibb (BMY
+1%), GlaxoSmithKline (GSK
+0.6%), Johnson & Johnson (JNJ
+0.6%), Eli Lilly (LLY
+0.7%), Merck (MRK), Novartis (NVS
+0.7%), Pfizer (PFE
+0.6%), Teva Pharmaceutical Industries (TEVA
+6.4%), Amgen (AMGN
+0.9%), Biogen (BIIB
+3.1%), Gilead Sciences (GILD
+1%), Vertex Pharmaceuticals (VRTX
+0.3%)
ETFs: (XPH
+3.4%), (XBI
+0.9%), (IBB
+0.9%), (PJP
+1.2%), (IHE
+2.3%), (PPH
+0.6%), (XLV
+0.1%) | 2019-06-26T00:00:00 | 2019-06-26T00:00:00 | 166.720001 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 |
2019-06-26 | VRTX | Healthcare stocks under pressure ahead of Dem debate | Medical stocks are largely in the red in early trade, extending their near-term selloff ahead to tonight's first debate between Democratic presidential hopefuls in Miami. All have proposed various schemes for extending healthcare coverage and corralling drug price increases.
Selected tickers: Health Care Select Sector SPDR ETF (XLV
-1.2%), Vanguard Health Care ETF (VHT
-1.3%), Abbott (ABT
-1.3%), AstraZeneca (AZN
-1.3%), Bristol-Myers Squibb (BMY
-0.8%), GlaxoSmithKline (GSK
-1%), Johnson & Johnson (JNJ
-2%), Eli Lilly (LLY
-2.9%), Novo Nordisk (NVO
-0.5%), Novartis (NVS
-1.2%), Pfizer (PFE
-1.5%), Amgen (AMGN
-0.5%), Biogen (BIIB
-1.5%), Gilead Sciences (GILD
-2%), Vertex Pharmaceuticals (VRTX
-0.9%), Nektar Therapeutics (NKTR
-3.3%), Regeneron Pharmaceuticals (REGN
-1.9%), Incyte (INCY
-1.5%), Sage Therapeutics (SAGE
-1.2%), UnitedHealth Group (UNH
-1.1%), Cardinal Health (CAH
-0.2%), McKesson (MCK
-1.2%), AmerisourceBergen (ABC
-0.6%), Tenet Healthcare (THC
-1.8%), HCA (HCA
-1.5%), Humana (HUM
-0.2%) | 2019-06-27T00:00:00 | 2019-06-27T00:00:00 | 166.880005 | 170.229996 | 168.729996 | 165.729996 | 169.119995 | 172.369995 | 173.009995 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 |
2019-07-08 | VRTX | Biotechs and biopharmas under pressure ahead of Trump order on drug prices | Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursement rates will match those in the country paying the lowest prices instead of an index of drug prices from around the world.
Pushback from manufacturers should be substantial. The fireworks will, no doubt, be good theatre.
ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, CHNA, IDNA, XLV, XBI, PJP
Selected tickers:Â Amgen (AMGN
-2.5%), Biogen (BIIB
-2.1%), Gilead Sciences (GILD
-2.5%), Vertex Pharmaceuticals (VRTX
-1.7%), Merck (MRK
-2.2%), Eli Lilly (LLY
-1.4%), Bristol-Myers Squibb (BMY
-1.1%), Pfizer (PFE
-1.7%), Novartis (NVS
+0.3%), Roche (OTCQX:RHHBY
-0.7%), AbbVie (ABBV
-2.5%), Bausch Health Companies (BHC
-2%), Teva Pharmaceutical Industries (TEVA
-2.3%), AstraZeneca (AZN
-0.5%), GlaxoSmithKline (GSK
-0.5%), Johnson & Johnson (JNJ
+0.1%), Takeda (TAK
-0.6%), Allergan (AGN
-1.3%) | 2019-07-09T00:00:00 | 2019-07-09T00:00:00 | 171.770004 | 172.759995 | 166.550003 | 170.259995 | 166.179993 | 166.639999 | 171.270004 | 173.270004 | 167.75 | 173.509995 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 |
2019-07-22 | VRTX | Vertex files U.S. application for triplet CF regimen VX-445 | Vertex Pharmaceuticals (NASDAQ:VRTX) has submitted a marketing application to the FDA seeking approval for VX-445 (elexacaftor, tezacaftor and ivacaftor) for the potential treatment of cystic fibrosis (CF) patients at least 12 years old with one F508del mutation and one minimal function mutation or two F508del mutations.
The company has requested Priority Review which, if granted, will shorten the review clock to eight months from the time of submission from 12 months. | 2019-07-23T00:00:00 | 2019-07-23T00:00:00 | 172.839996 | 172 | 170.630005 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 |
2019-07-25 | VRTX | Dosing underway in mid-stage CF study of Proteostasis combo therapies | The first patient has been dosed in a Phase 2 clinical trial evaluating Proteostasis Therapeutics' (PTI
-1.6%) doublet therapy (PTI-808 and PTI-801) and triplet therapy (doublet + PTI-428) in up to 30 F508del homozygous cystic fibrosis (CF) patients and up to 30 F508del heterozygous CF patients.
PTI-808 is a potentiator, PTI-801 is a CFTR corrector and PT428 is a CFTR amplifier.
Preliminary data should be available in Q1 2020.
CF-related tickers: Vertex Pharmaceuticals (VRTX
-1.6%), AzurRx BioPharma (AZRX), Eloxx Pharmaceuticals (ELOX
-1.8%) | 2019-07-26T00:00:00 | 2019-07-26T00:00:00 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 | 179.529999 | 181.119995 | 184.940002 |
2019-07-25 | VRTX | Vertex sets CEO transition April 1 | Vertex Pharmaceuticals (NASDAQ:VRTX) announces that, on April 1, 2020, Chairman, President & CEO Jeffrey Leiden will transition to Executive Chairman while Chief Medical Officer Reshma Kewalramani, M.D. will succeed him as President & CEO. | 2019-07-26T00:00:00 | 2019-07-26T00:00:00 | 168.889999 | 170.220001 | 173.779999 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 | 179.529999 | 181.119995 | 184.940002 |
2019-07-30 | VRTX | Vertex Pharmaceuticals Q2 2019 Earnings Preview | Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q2 earnings results on Wednesday, July 31st, after market close.
The consensus EPS Estimate is $1.07 (+13.8% Y/Y) and the consensus Revenue Estimate is $884.66M (+17.6% Y/Y).
Over the last 2 years, vrtx has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 12 upward revisions and 6 downward. Revenue estimates have seen 8 upward revisions and 4 downward. | 2019-07-31T00:00:00 | 2019-07-31T00:00:00 | 177.940002 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 | 179.529999 | 181.119995 | 184.940002 | 187.089996 | 183.720001 | 186.399994 |
2019-07-31 | VRTX | Vertex Pharma up 2% after hours on Q2 beat, guidance raise | Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 results ($M): Revenues: 941.3 (+25.1%); product sales: 940.4 (+25.4%).
Key product sales: Symdeko/Symkevi: 362 (+94.6%); Orkambi: 316 (+69.9%); Kalydeco: 262 (+3.6%).
Net income: 267.4 (+28.9%); non-GAAP net income: 327.3 (+34.1%);Â EPS: 1.03 (+28.8%) non-GAAP EPS: 1.26 (+34.0%).
2019 guidance: Product sales: $3.60B - 3.70B from $3.45B - 3.55B.
Shares up 2% after hours.
Previously: Vertex Pharmaceuticals EPS beats by $0.19, beats on revenue (July 31) | 2019-08-01T00:00:00 | 2019-08-01T00:00:00 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 | 179.529999 | 181.119995 | 184.940002 | 187.089996 | 183.720001 | 186.399994 | 184.210007 |
2019-07-31 | VRTX | Vertex Pharmaceuticals EPS beats by $0.19, beats on revenue | Vertex Pharmaceuticals (NASDAQ:VRTX): Q2 Non-GAAP EPS of $1.26 beats by $0.19; GAAP EPS of $1.03 beats by $0.27.
Revenue of $941.3M (+25.5% Y/Y) beats by $56.64M.
Shares -1.7%.
Press Release | 2019-08-01T00:00:00 | 2019-08-01T00:00:00 | 181.75 | 182.169998 | 183.970001 | 181.020004 | 180.149994 | 177.660004 | 178.580002 | 183.380005 | 181.839996 | 179.529999 | 183.259995 | 178.339996 | 176.75 | 178.460007 | 178.759995 | 176.009995 | 175.789993 | 176.369995 | 176.160004 | 177.139999 | 178.089996 | 174.130005 | 174.080002 | 175.240005 | 173.339996 | 169.559998 | 166.830002 | 166.229996 | 169.539993 | 166.619995 | 179.289993 | 178.389999 | 175.559998 | 176.940002 | 175.649994 | 182.940002 | 182.979996 | 179.839996 | 183.910004 | 179.529999 | 181.119995 | 184.940002 | 187.089996 | 183.720001 | 186.399994 | 184.210007 |